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ii. ABBREVIATIONS 
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AJCC  American Joint Committee on Cancer 
ANOVA analysis of variance 
AP   adenoviral protease 
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C4BP   C4-binding protein 
CAR   coxsackie and adenovirus receptor 
CD   cytosine deaminase 
CD4   cluster of differentiation 4 
CD8   cluster of differentiation 8 
cDNA complementary DNA 
CoCa  colorectal cancer 
CRAD Conditional replicative adenovirus 
CREB  cAMP response element binding protein 
CT   computerized tomography 
CtBP1  C-terminal binding protein 1 
- 3 - 
 
CTL   cytotoxic T lymphocyte 
Da   Dalton 
DAI   DNA-dependent activator of IFN-regulatory factors 
DBP   DNA-binding protein 
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IL-1   interleukin 1 
IL-1R  interleukin 1 receptor 
ITR   internal terminal repeat  
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PML   promyelocytic leukemia 
Pol   DNA polymerase 
pTP   pre-terminal protein 
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Y  tyrosine 
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iii. ABSTRACT 
Despite the rapid advance of cancer research and improvement of conventional 
therapeutic regimes like chemotherapy, surgery, immunotherapy or radiotherapy, 
cancer remains a leading cause of death worldwide. Metastatic disease normally 
represents the most deadly stage and leads to the poorest prognosis. The disseminated 
location  of  metastases  makes  it  even  more  difficult  nowadays  for  existing  drugs  to  
target tumors  without damaging healthy tissues. The work presented in this Doctoral 
Thesis is aimed at developing targeted adenoviral vectors and regimes that can be 
applied to the treatment of cancer, especially colorectal cancer. 
Gene therapists have explored widely interactions of the viruses to cancer and normal 
cells and have proved that molecular modifications in the capsid can unleash striking 
differences in viral tropism. In this Doctoral Thesis, the utility of arginine-glycine-
aspartic acid (RGD) targeting ?v? integrins substituted for the lysine-lysine-threonine-
lysine  (KKTK)  domain  of  the  fiber  shaft  or  inserted  in  the  HI-loop  of  adenovirus  
serotype 5 (Ad5) was evaluated for increased tumor targeting and antitumor efficacy. 
Both modifications increased gene transfer efficacy in colorectal cancer cell lines and 
improved the tumor to-normal ratio after systemic administration of the vector. 
Furthermore, antitumor potency was not compromised with RGD modified viruses 
suggesting that an increased safety profile did not involve any loss of therapeutic effect. 
Treatments based on adenovirus vectors should not have negative effects on tumor 
progression or metastases. In order to evaluate this possibility, we designed a novel 
murine model of human colorectal cancer (CoCa) to test our treatments. To this end, we 
have developed a readily imageable mouse model of colorectal cancer featuring highly 
reproducible formation of spontaneous liver metastases derived from intrasplenic 
primary tumors. We optimized several experimental variables, and found that the 
correct choice of cell line and genetic background of the recipient mice as well as their 
age, were critical for the establishment of a useful animal model. A magnetic resonance 
imaging  (MRI)  protocol  was  optimized  for  use  with  this  mouse  model,  and  
demonstrated to be a powerful method for analyzing the antitumor effects of an 
experimental therapy.  
Poor spreading of the virus through tumor tissue is one of the major issues limiting 
efficacy of oncolytic adenoviruses, even after local administration by intratumoral 
injection.  In this study, ECM-degrading proteases relaxin, hyaluronidase, elastase, and 
macrophage metalloelastase (MME) were used to increase oncolytic adenovirus 
spreading. Moreover, MME improved the overall antitumor/antitumour efficacy of 
oncolytic adenovirus in subcutaneous HCT116 xenografts. In a liver metastatic 
colorectal  cancer  model,  intratumoral  treatment  of  HT29  primary  tumors  with  MME  
monotherapy or with oncolytic adenovirus inhibited tumor growth. Combination 
therapy showed no increased mortality in comparison to monotherapies. In addition, 
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our work demonstrated for the first time in a metastatic animal model that MME, as a 
monotherapy or in combination with an oncolytic virus, does not increase tumor 
invasiveness. Co-administration of MME and oncolytic adenovirus may be a suitable 
approach for further optimization of metastatic colorectal cancer treatment. 
To  summarise,  we  described  how  RGD  moieties  inserted  in  the  fiber  protein  are  
capable of improving tumor targeting of wild-type or capsid-modified adenovirus 
vectors. We also showed that MME is a safe coadjuvant to be used in combination with 
oncolytic adenoviruses for intratumoral administration and we presented a highly 
optimized mouse model for liver metastasis of colorectal cancer. 
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PART B 
1. REVIEW OF THE LITERATURE 
1.1. INTRODUCTION 
In 1953, Dr. Wallace Rowe was trying to find a causal agent for common flu in 
children adenoid tissue samples and isolated an unknown etiologic agent, probably 
a virus (Rowe et al. 1953). Subsequently, Dr. Harold S. Ginsberg succeeded in 
maintaining it in a established cell culture (HeLa cells) demonstrating its capability 
to make important morphological changes in cells, which were thought to represent 
viral replication (Ginsberg, 1999). Soon, it was confirmed that the new virus 
corresponded  with  the  etiological  agent  for  large  number  of  cases  of  an  acute  
respiratory disease among army recruits from different forts in the United States.  
The structure was proposed in 1959 (Horne, R.W., Brenner, S., Waterson, A.P., 
Wildy, P. 1959): the virion having DNA genome was described as an icosahedral 
particle with one fiber protein: at each apex that produced infections by interaction 
with  host  cells  through  its  fibers.  Several  names  were  given  to  the  new  agent:   
adenoid degeneration (AD), adenoid-pharyngeal conjunctival or acute respiratory 
disease (ARD), but finally consensus was established and the new virus was called 
Adenovirus (Enders et al. 1956).  
Adenoviruses are classified within the Adenoviridae family, that includes four genera: 
Mastadenovirus, Aviadenovirus, Atadenovirus and Siadenovirus. Mastadenovirus is 
found in mammals, while Aviadenovirus has been isolated from birds. The last two 
genera include  a  wide  range  of  host  species.  The  only  adenovirus  found  in  fish  is  
classified in a fifth clade (see figure 1) (Benko, Harrach 1998, Kovacs et al. 2003, 
Benko  et  al.  2002).  The  host  most  frequently  infected  by  each  virus  species  is  
indicated  with  a  letter  at  the  beginning  of  the  name,  while  the  last  letter  
distinguishes the species within each genus. Sometimes, a number can be added at 
the end to indicate the serotype. For example, BAdV-B mostly infects bovine hosts 
and belongs to genus Mastadenovirus species B(Benk?, M., Harrach, B., Russell, W. 
C. 2000). 
Human  adenoviruses  include  6  species:  A,  B,  C,  D,  E  and  F  according  to  the  
capability to agglutinate erythrocytes of different species and the oncogenicity they 
present in rodents. Species B can be subdivided into B1 and B2. Although species 
are not classified according to their tissue tropism, for example, species B1, C and E 
mainly invade the respiratory system, while species B, D and E can induce ocular 
diseases. In parallel, human adenoviruses can be divided into 51 different serotypes 
according to how they are neutralized by a specific antisera (Russell, 2009). Species 
A includes Ad12, 18 and 31; species B: Ad 3, 7, 11, 14, 16, 34, 35 and 50; species C: 
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Ad1, 2, 5 and 6; species D: Ad8-10, 13, 15, 17, 19, 20, 22-30, 33, 36-39, 42-49 and 51; 
species E: Ad4; species F: Ad40 and 41(Berk AJ 2007). 
 
 
 
 
Figure 1: Phylogenetic tree of Adenoviridae family 
Adapted from Davison et al., 2003 (Davison, Benko & Harrach 2003) 
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1.2. ADENOVIRUS BIOLOGY 
1.2.1. Viral structure 
Adenoviruses are non-enveloped viruses with double-stranded lineal DNA 
genome. They measure around 90 nm in diameter and have an approximate mass 
of 150 x 106 Da. Viral capsid proteins comprise 87% of the mass, while the rest (1%) 
comes from the genome. Adenovirus capsid is composed of three major proteins: 
hexon, penton base and fiber proteins. These proteins are assembled together with 
four  minor  structural  proteins:  proteins  IIIa,  VI,  VIII  and  IX  (Berk  AJ  2007).  See  
figure 2 for a complete understanding of location and organization of the structural 
proteins.  The  lineal  DNA  genome  measures  around  36  kb  and  is  tightly  packed  
inside the capsid by four  proteins:  V,  VII,  ?,  IVa and the terminal  protein (TP).  It  
also contains several copies of adenoviral protease (AP) (Russell, 2009). 
 
 
 
Figure 2: Structure of Adenovirus sp. 
Structural proteins in a Adenovirus sp. particle. Modified from Chailertvanitkul et al, 2010 (Chailertvanitkul, 
Pouton 2010) 
 
 
1.2.2. Capsid proteins 
1.2.2.1. Hexon 
The  Hexon  protein  or  polypeptide  II  is  located  at  the  20  facets  of  the  icosahedral  
capsid and represents 63% of the adenovirus molecular mass.  The size of the hexon 
varies between serotypes, the biggest hexon capsomers are 967 aa and are found in 
Ad2 (Russell, 2009). 240 hexon capsomers are present in every adenovirus particle 
and present a pseudo-hexagonal conformation that is surrounded by six other 
elements, either hexon or penton capsomers (Berk AJ 2007, Rux, Burnett 2004).  
The  hexon  is  a  trimeric  protein  with  three  repetitions  of  two  similar  domains  (V1 
and V2) assembled in a characteristic structure known as ?-barrels (see figure 3A). 
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Such a conformation is found in many spherical viruses and provides important 
resistance to proteolysis. While the base of the protein is highly conserved, the top 
part ends in three “tower” domains that contain up to nine hypervariable regions 
(HVR)  in  total.  These  regions  are  related  to  the  antigenicity  of  the  hexon  and  are  
most responsible for the raise of neutralizing antibody activity over the adenovirus, 
thus determining the viral serotype (Rux, Burnett, 2004; Berk AJ, 2007; Russell, 
2009). 
 
 
 
 
Figure 3: Hexon protein 
A: Trimeric hexon protein structure from the side (upper) and from the top, i.e. external side of the virion  
(lower). Equivalent monomers are depiced in the same color modified from Roberts et al., 2006. B: External 
view of the particle showing the hexon proteins organization (adapted from Rux et al., 2004). C: Organization 
of the different types of hexons with other structural proteins in the viral particle facet (modified from Campos 
et al., 2007. 
 
There are four types of hexons, located in specific parts of each facet and subjected 
to very different environments. A single adenoviral particle contains six H1 hexon 
capsomers that are associated with the twelve pentons located at the apices and H2, 
H3 and H4 commonly named “groups of nine (GON)” that are situated at the 
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center of the facets and only interact with other hexons and structural proteins, but 
never with penton capsomers (figure 3C) (Russell, 2009). 
Owing to high level of conservation of the hexon base, it is possible to create 
chimeric viruses by the  replacement of hexons for other serotypes, with the aim of 
avoiding serotype-specific neutralization by antibodies and gaining tolerance to 
repeated administration of adenovirus-based vectors (Wu et al. 2002a; Tian et al., 
2011). For the same purposes, specific loops in the variable region can be 
substituted for different serotypes (Gall, Crystal & Falck-Pedersen 1998, Roy et al. 
1998). 
 
1.2.2.2. Penton base 
Penton is a covalent complex of two proteins: the homopentameric penton base 
(polypeptide III) and the homotrimeric fiber (polypeptide IV). Its name is due to its 
capability  to  bind  to  five  different  capsomers  at  a  time.  Penton  base  proteins  are  
located on the twelve vertices of the icosahedrons and are responsible for the 
attachment  and  internalization  of  the  virus  to  the  host  cell  (Berk  AJ,  2007;  
Nemerow, Stewart 1999).  
The  penton  base  monomer  is  comprised  of  471  aminoacids  for  Ad2.  Its  structure  
was resolved by Stewart et al. (Stewart et al. 1991) as a complex of two domains: a 
basal jelly-roll domain and an upper unit with irregular folds as well as two arising 
loops. The first loop contains the RGD (Arginine – Glycine – Aspartic Acid) motif 
loop and the second loop, also called the variable loop, differs in its length and 
characteristics depending on the serotype (figure 4B). The RGD motif is necessary 
for fiber interaction with host cell surface ?v integrins, an essential step for the 
internalization of adenovirus subgroups A, B, C and E (Russell 2009; Rux, Burnett 
2004; Zubieta et al. 2005). See figures 4A, 4B and 4C. 
Pentamerization of the penton base provides stability, since it hides hydrophobic 
surfaces, and creates a central hole of around 30 Å diameter that is filled by the fiber 
protein. The binding of fiber and penton base occurs through the fiber motif 
FNPVYPY, located in five equivalent fiber-binding sites in the penton base (Rux, 
Burnett 2004; Zubieta et al. 2005).  
In the absence of other virion components, some pentons can assemble by 
themselves and create dodecahedral complexes. Interestingly, in many serotypes, 
penton base proteins are produced in excess, so dodecahedral complexes efficiently 
enter the cells and accumulate at the nuclear membrane (Schoehn et al. 1996, Fender 
et al. 2005, Zubieta et al. 2005). 
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Figure 4: Penton and fiber proteins 
Lateral (A) and top (C) view of the penton protein and the location of the RGD and variable loops (B). Fiber 
protein, its two domains: knob and shaft and binding loci to CAR and heparan sulfates (D). A and B have 
been adapted from Zubieta et al., 2005. C and D were modified from Zhang and Bergelson, 2005 
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1.2.2.3. Fiber 
The fiber protein consists of 582 residues. This protein plays a significant role on 
virion structure stabilization, hence virions lacking fibers are less stable and leak 
DNA out of the capsid (Zubieta et al. 2005; Von Seggern et al. 1999).  
The fiber protein is trimeric and divided in three different domains: a tail that 
attaches to the penton base in the N-terminus, a fiber shaft with around 15 repeated 
motives and a globular knob domain in the C-terminus that plays a central role in 
cell surface protein recognition (Rux, Burnett 2004). 
The N-terminus of the trimeric protein binds to the pentameric penton base. This 
symmetry mismatch caused much controversy in the scientific community until the 
discovery that the binding of the fiber triggers conformational changes in the 
penton base that make the binding to exactly three fiber proteins exclusive. This 
binding  is  mediated  by  the  FNPVYPY  sequence,  with  the  complementation  of  
several hydrogen bonds and a salt bridge (Zubieta et al. 2005; Russell 2009). 
The fiber shaft consists of six (in Ad3) to 22 (in Ad2 and Ad5) sequence repetitions 
(Berk AJ 2007) arranged in a unusual triple ?-spiral fold topology. The fiber knob 
structure contains eight-stranded ?-barrels that form the core of each subunit, with 
a central depression and three valleys in a conformation that differs importantly 
from the hexon and penton. The binding to cell membrane components depends on 
several loops named DG, HI and AB, all emanating from the knob domain (figure 4 
D).  The Binding of  Ad5 to  different  cell  receptors  will  be  further  discussed in  the 
section 1.2.3.1 (Russell 2009). 
 
1.2.2.4. Minor capsid proteins 
Minor capsid proteins (IIIa, VI, VIII and IX) are also called cement proteins because 
of  their  role  in  assembling and keeping the rest  of  structural  proteins  together.  In  
addition to that, they are involved in the efficient disassembly of the virion during 
infection. Unfortunately, their structure is not yet well-known, for only a few 
crystallographic data are available (Rux, Burnett 2004).  
Protein IIIa is a 570 aa (for Ad2) polypeptide positioned below the penton base, on 
the exterior of the capsid. Its helical structure-based N-terminal binds at the same 
time  to  the  penton  base,  hexons  and  protein  VI.  By  doing  so,  it  stabilizes  the  
interface between facets (Rux, Burnett 2004; Russell 2009). 
Polypeptide VI (500 aa for Ad2) contains two long ?-helices, one of them binds to 
the cavity in the base of the hexon and to protein III at the apices. Its distribution in 
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the  capsid  is  not  clear:  the  low  number  of  VI  per  viral  particle  suggests  a  non  
homogenous distribution within the facet but a exclusive binding to peripentonal 
hexons (Russell 2009; Rux, Burnett 2004; Fabry et al. 2005). By this way, protein VI 
plays a cementing role during viron assembly. Its N-terminus is basic and interacts 
with the nucleic acid inside the capsid, while the C-terminus is an activator of the 
adenovirus protease (AP). This mechanism ensures that hexon, DNA and cement 
protein are spatially and temporally close before the assembly of the capsid 
vertexes (Mangel, Baniecki & McGrath 2003). 
The 140 aa (for Ad2) protein VIII is probably located in the inner side of the capsid 
in two different positions: five copies surround the peripentonal (H1) hexons 
connecting them to the GONs, while three copies are located around the axes and 
stabilize the GONs (Russell 2009, Rux, Burnett 2004; Fabry et al. 2005).  
Polypeptide  IX  (140  residues  for  Ad2)  is  located  in  the  center  of  central  hexon  
interfaces  in  the  exterior  surface  of  the  capsid.  Its  structure  is  based  on  the  high  
propensity to arrange itself in coiled coils. The N-terminus of protein IX  is 
responsible for the attachment to the capsid and its stabilization (Russell 2009). 
Meanwhile, the C-teminus interacts with the HVR-4 loop of the hexon and is 
involved in other roles related to viral replication. For example, it binds to TATA-
containing promoters, acting as a transcriptional activator of adenovirus late genes. 
Another property of IX is to form amorphous inclusions, which are structures that 
block interferon-mediated antiviral activity of the host cell (Rux, Burnett 2004, Parks 
2005). Protein IX has been extensively modified to generate fusion proteins for gene 
therapy applications (Meulenbroek et al. 2004; Parks 2005). 
 
1.2.2.5. Virion core proteins 
The  virus  core  includes  the  viral  genome  plus  structural  proteins  V,  VII,  ? and  
terminal protein (TP). Some authors also include polypeptide IVa2 and the 
adenovirus protease (AP) in this group (Russell 2009, Berk AJ 2007).  
Polypeptides V, VII and ? are basic proteins (rich in arginine residues) so they can 
attach to  DNA and condense it  within the core.  Polypeptide VII  is  the  major  core  
protein (800 copies per virion) and mainly responsible for DNA organization into a 
condensed nucleoprotein.  Protein V is  strongly associated with the capsid protein 
VI, polypeptide VII and viral DNA, thus providing stabilization of the core 
nucleoproteins and the capsid. ? is an arginine-rich DNA interacting protein, but its 
disposition in the core is not clear. Protein IVa2 binds to a specific region of the viral 
DNA and has a critical role in its packaging process. Similarly, terminal protein 
(TP) interacts selectively with the 5’terminus of the DNA strand (Russell 2009, Berk 
AJ 2007).  
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Adenoviral protease (AP) or adenain contains two different domains and a polar 
interface (McGrath et al. 2003). It is non-specifically activated by binding to viral 
DNA, but requires binding to protein VI C-terminus to achieve its optimal activity. 
This protease is necessary to cleave capsid precursor to mature structural proteins 
IIIa, VI, VII VIII,  TP and ? in order to complete the encapsidation process (Russell 
2009, Mangel, Baniecki & McGrath 2003; McGrath et al. 2003). 
 
1.2.2.6. Adenovirus genome 
Adenovirus 2 was the first adenovirus to be completely sequenced. Some years 
later, Adenovirus 5 sequence was also described (Chroboczek, Bieber & Jacrot 
1992). Adenovirus genome consists of a linear double-stranded DNA of around 36 
kb. It is flanked at both ends by two identical inverted terminal repeats (ITR) 
ranging in size from 36 to more than 200 bp depending on the adenovirus species 
(Berk AJ 2007). At the 5’-end of each ITR a 55 kDa terminal protein (TP) is 
covalently bound and acts as replication initiator, being the ITRs origins of 
replication. Other elements necessary for replication are DNA polymerase (pol) and 
the  DNA  binding  protein  (DBP)  (de  Jong,  van  der  Vliet  &  Brenkman  2003,  King,  
van der Vliet 1994). A cis-acting packaging sequence, named ?, is essential for viral 
encapsidation. It is located between the left terminal repeat and the first protein 
coding region (E1A) (Hearing et al. 1987). 
 
 
 
Figure 5: Adenovirus sp. transcription map 
Adenovirus genome includes eight transcription units grouped in five early transcription units, two 
intermediate transcription units and one late transcription unit, under the control of the Major Late Promoter 
(MLP). The early transcription unit is depiced, by consensus, on the left of the transcription map.  
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The adenoviral genome is divided into transcription units: five early transcription 
units (i.e. E1A, E1B, E2, E3 and E4); three delayed early transcription units (i.e. IX, 
IVa,  E2  late)  and  one  late  transcription  unit,  under  control  of  the  major  late  
promoter (MLP) that is processed to five families of late mRNA: L1-L5 (see figure 
5).  This  disposition of  the different  genes  along the genome is  responsible  for  the 
development of the adenovirus infectious cycle in two subsequent phases, as will be 
further discussed in the section 1.2.3.4. (Berk AJ 2007; Russell 2000). While DNA 
sequences encoding most structural proteins and proteins involved in viral 
replication and assembly are largely conserved between all adenovirus species, 
other DNA sequences are genus-exclusive  (Davison,  Benko  &  Harrach  2003).  By  
consensus, the genome map is drawn with the E1A gene at the left end (figure 5). 
 
1.2.3. Life cycle 
Adenovirus infects eukaryotic cells through interaction with cell surface receptors. 
The viral genome is internalized to the cell by an endocytic process and delivered to 
the nucleus by active transportation through microtubules (figure 6). Viral 
replication occurs in two subsequent phases. Release of new virions is mediated 
exclusively by cell lysis. The complete life cycle of Adenovirus serotype 5 will be 
described in the following sections 1.2.3.1 – 1.2.3.6. 
 
1.2.3.1. Interaction with host cell 
Cell attachment by Ad5 is mainly mediated by its interaction with Coxsackie and 
Adenovirus  Receptor  (CAR).  CAR  is  a  member  of  the  immunoglobulin  (Ig)  
superfamily with two Ig-like domains, a transmembrane anchor and a cytoplasmic 
tail of 107 aminoacids (Bergelson et al. 1998) (figure 6A). CAR expression is mainly 
associated with tight junctions in the basolateral surface of polarized epithelial cells. 
This is why it is unlikely that natural adenovirus infections start by binding to CAR 
in tight junctions; it is more likely that infection starts either in subpopulations of 
non-polarized cells that expose CAR to the luminal membrane or through lesions 
present before the adenovirus infection that will expose the basolateral membrane 
to adenovirus (Meier, Greber 2004). In any case, after viral infection, viable 
particles, together with an excess of fiber proteins, are released to the extracellular 
space where they interact with CAR and produce the disruption of tight junctions 
(figure 6A). Consecutively, the morphology of epithelial cells changes to a 
discontinuous and abnormally permeable layer, through which thradenovirus can 
easily reach the apical compartment (Walters et al. 2002).  
The first interaction of the viral particle with the cell occurs through CAR binding 
to the fiber knob. Interestingly, CAR does not interact with the distal extreme of the 
fiber knob but with several loops located on the sides. Specifically, the Ig-like 
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domain  of  CAR  binds  to  the  AB  loop  that  is  highly  conserved  among  the  
adenovirus species that use CAR (i.e. species A and C) (Nemerow et al. 2009). Given 
the location of the AB loop in the lateral part of the knob, fiber flexibility is essential 
for optimal CAR binding, as well as the length of the fiber shaft that depends on the 
number of ?-repeat elements it possesses. Several studies estimate that the fiber 
should contain between 5.5 and 22.5 elements to permit optimal binding 
(Shayakhmetov, Lieber 2000). 
 
 
Figure 6: Infection and DNA transfection by Adenovirus particles 
Interaction of fiber knob with CAR receptor followed by binding of penton base to cell surface integrins (A). 
Viral internalization through clathin-coated vesicles (B) and formation of an endosome (C). Degradation of the 
viral capsid occurs mainly in the endosome and is accompanied by a pH decrease (D). Viral particles are 
translocated to the perinuclear compartment by the dynein protein through the microtubules (E-F). Adapted 
from Medina-Kauwe et al., 2003  
 
Immediately  after  CAR  binding,  a  second  interaction  occurs:  ?v integrins on the 
host  cell  external  surface  bind  to  the  RGD  domain  that  is  located  in  one  of  the  
variable loops of the penton base. Once again, the fiber needs to be flexible enough 
to guarantee a correct binding (Russell 2009, Nemerow et al. 2009). Rather than 
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enhancing virus attachment, penton-integrin binding promotes virus infection by 
activating internalization through clathrin-coated vesicles (Russell 2009, Nemerow 
et al. 2009) (figure 6B). 
Unexpectedly, studies done with adenovirus with mutated CAR-binding domains 
in the AB loop showed significant decrease for in vitro infectivity, but a similar rate 
of in vivo transfection to hepatocytes (Alemany, Curiel 2001, Smith et al. 2002).This 
casted many doubts on the theory of a unique role of CAR-integrin receptors in the 
adenovirus infection and suggested that an alternative route for adenovirus entry 
existed. Indeed, Ad5 can also infect cells by the interaction of its KKTK domain, 
located in the third ?-repeat of the fiber shaft, with cell heparan sulfate 
proteoglycans (HSPG) (Dechecchi et al. 2001, Dechecchi et al. 2000). It has been 
shown that ablation of the KKTK domain, by mutation to GAGA, dramatically 
reduces in vivo delivery to hepatocytes (Smith et al. 2003, Rittner et al. 2007, Bayo-
Puxan et al. 2006). However, the data concerning the role of the KKTK motif in liver 
cell infection is controversial and some studies reveal that the direct interaction of 
KKTK domain with HSPG is irrelevant for in vivo liver cell infection after systemic 
administration (Di Paolo, Kalyuzhniy & Shayakhmetov 2007, Rogee et al. 2008). 
Other alternative explanations for these results with KKTK-ablated chimeric virus 
are related to the fiber flexibility loss due to structural changes caused by the 
mutation or alterations in post-internalization (Kritz et al. 2007). 
In  recent  years,  data  has  proved that  blood factors,especially  factor  X,  is  the  main 
determinant of Ad5 biodistribution in vivo, leaving CAR with little or no role. In this 
case,  access  to  the  host  cell  occurs  by  non-fiber  mediated  entry  mechanisms,  but  
through binding of factor X to the hexon protein and subsequent binding to HSPG 
on liver hepatocyes (Alba et al. 2009). Although hexon protein plays a major role on 
Ad5 initial attachment and transduction at the host cell, binding of integrins to 
penton base RGD motif is necessary for correct internalization and intracellular 
transportation to perinuclear compartment. This process is necessary for effective 
replication of the virus (Bradshaw et al. 2010). Other blood components, like 
complement system’s proteins C3 or C4Bp, lactoferrin and factor IX, have also 
shown to participate and enhance liver transfection (Shayakhmetov et al. 2005b). 
 
1.2.3.2. Adenovirus internalization 
Independently of the receptor used for a first interaction of the viral capsid with the 
host cell,  penton base-integrin binding is necessary for a rapid uptake of the virus 
into the cell in a process called internalization (figure 6B-D). The integrins that 
mediate in this binding are subtyes ?v?1,  ?v?3 and ?v?5 (Nemerow et al. 2009, 
Smith et al. 2010, Shayakhmetov et al. 2005a, Nemerow, Stewart 1999, Bradshaw et 
al. 2010). Integrins are cell membrane proteins that participate in many important 
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cell biological processes, like cell adhesion, migration, differentiation and 
proliferation. They are heterodimeric proteins comprised of two non-covalently 
bound  subunits:  ? and  ? (Ruoslahti,  Pierschbacher  1987).  Integrins  bind  to  RGD  
sequences present in components of the extracellular matrix (ECM) like vitronectin 
(Ruoslahti,  Pierschbacher 1987). RGD motives are conserved in the penton base in 
most  adenovirus  serotypes.  The  spacing  of  the  RGD  loops  in  the  penton  base  
permits to maximize the binding properties and allow up to 4-5 integrins to be 
bound to each pentamer (Nemerow et al. 2009). 
Viral internalization triggers several cell responses, such as activation of cell 
signaling that leads to the polymerization of actin filaments, a process needed for 
the rapid internalization of the virus into clathrin-coated pits and vesicles (Wang et 
al. 2000). Adenovirus infection also promotes formation of post-translationally 
modified more stable microtubules, utilized by adenovirus for their efficient 
translocation to the nucleus and rapid onset of viral gene replication (Warren, 
Cassimeris 2007) (figure 6E-F).  
 
1.2.3.3. Adenovirus uncoating and genome delivery to the cell nucleus 
After integrin-mediated endocytosis, the virus is still topologically out of the cell. 
Before being delivered to the nucleus, the viral genome still needs to cross three 
barriers: the capsid of the virus particle, the endosomal membrane and nuclear 
envelope. Uncoating is described as the dissolution of the first barrier, the viral 
capsid, and occurs in several subsequent stages. The first step consists of vertex 
dissociation. Vertices are structurally weak parts of the capsid. Adenovirus particles 
are assembled in such a manner that the association between penton and 
peripentonal hexons is labile. The vertex removal mechanism is not fully known, 
but it is suspected to be dependent on integrin engagement. It is not known either 
whether the fiber or the entire penton-fiber complex is removed together (Smith et 
al. 2010).  
After  vertex  removal,  the  virus  goes  through  several  uncoating  steps  inside  the  
endosome. This process progresses with loss of peripentonal hexons and proteins 
IIIa, VIII, IX and VI. The interaction between the peripentonal hexons and the rest of 
the facet is different to the interphase between hexons within the facets. This 
explains why central hexon complexes can remain in the endosome after complete 
uncoating. 
The endosomal membrane represents the second barrier for genome delivery. Not 
until this membrane is permeable, can the genome escape the endosome and make 
its way to the nucleus. However, how the virus turns this membrane permeable is 
another  point  of  controversy between scientists.  While  former studies  point  to  the 
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penton base as responsible for the unstabilization of endosomal membranes, more 
modern studies claim that such a hypothesis is not valid (Greber et al. 1996). Protein 
VI is another candidate to be the architect of endosomal membrane 
permeabilization. First because it shows lytic activity over cell membranes, and 
second because  its presence is essential for proper genome delivery to the cell 
through endosomes (Wiethoff et al. 2005). Integrin binding exposes sites in protein 
VI that are vulnerable to adenovirus protease (AP) cleavage, once AP becomes 
activated by the reducing environment of the endosomes (Smith et al. 2010). Hence, 
AP that  is  responsible  for  the cleavage and maturation of  several  capsid proteins,  
also plays a role in adenovirus entry.  
Once the endosome is disrupted and most of the capsid proteins are uncoated and 
released to the cytoplasm, the hexons interact with dynein, a cytoplasmic protein 
that permits cytoplasmic transportation of virions along the microtubules towards 
the nucleus. By the time the subviral capsid reaches the nuclear pore complex, it is 
mainly composed of hexon proteins and viral DNA: hexon facets are estabilized by 
protein IX and the viral DNA is condensed by proteins VII, V and X. At this point, 
protein IX on the hexons of the subviral particle attach to the kinesin-1 light chain, 
which remains bound to the microtubules, thus releasing the GON trimers. In 
parallel, some kinesin-1 proteins are removed from the nuclear pore complex 
(NPC), causing its disruption. This allows the viral DNA import to the nuclear 
compartment (Strunze et al. 2011). The virus undergoes further uncoating at the 
nucleus pore and the viral genome is transferred to the nucleus (Leopold et al. 2000, 
Leopold, Crystal 2007, Strunze et al. 2005). Inside the nucleus, the terminal protein 
(TP) binds to the nuclear membrane through an interaction with lamin B and the 
genome is ready to start its replication (Russell 2000). 
 
1.2.3.4. Genome transcription and replication 
Adenovirus transcription occurs in two-phases: early and late. As explained in the 
section 1.2.2.6., the genome is divided into early, intermediate and late transcripted 
genes.  
Early  transcripted genes  encode for  five  transcription units:  E1A,  E1B,  E2,  E3 and 
E4.  The  first  viral  transcription  unit  to  be  expressed  is  E1A  that  includes  two  
transcripts and translates proteins 289R and 243R. E1A proteins act as trans-
activators for other early transcription units, i.e.: E1B, E2, E3 and E4. In general 
terms, they force the cell to S-phase in order to permit viral replication. They do so 
by interacting with many cellular proteins, the effects on the Retinoblastoma (Rb) 
pathway being of special importance for viral vector design.  Rb is a tumor 
suppressor protein whose mechanism of action involves binding and blockage of 
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E2F, a transcriptional activator required for the onset of S-phase. (McConnell, 
Imperiale 2004; Russell 2000; Nemajerova et al. 2008).  
 
Table 1: Interactions between adenovirus and host cell proteins that induce activation of the host cell (Berk 
AJ 2007) 
Gene / 
transcription 
unit 
Adenoviral 
gene product 
Host cell target Function Effect 
E1A 
243 / 12S / 
small E1A 
protein 
p300 histone acetylase Activation of E1B 
promoter 
 
Entry into S-phase 
CREB-binding protein 
E1A (12S 
and/or 
289/13S/large 
E1A) 
pRb Release of E2F 
p107 Release/activation of 
E2F 
 
p130 
p400 complex Transcription repression 
 CtBP1 
MLP Activation of MLP 
Expression of late 
mRNAs 
E1B E1B-55K p53 Degradation of p53 
Inhibition of cell 
cycle arrest and 
apoptosis 
E1B E1B-19K Bak / Bax 
Inhibition of 
mitochondrial 
membrane pores 
formation 
Inhibition of 
apoptosis 
E4 
E4orf1 
PDZ-containing proteins in 
plasma membrane 
mTOR activation 
High rate of protein 
synthesis in 
absence of 
mitogens and 
nutrients 
E4orf4 phosphatase PP2A 
E4orf6 
 
p73 Transcription activation Inhibition of cell 
cycle arrest and 
apoptosis 
p53 Degradation of p53 
(association with E1B-
55K) 
Degradation of MRN Inhibition of DNA 
damage response 
E4orf3 PML nuclear bodies Inactivation of MRN 
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Many  other  gene  products  co-operate  with  E1A  in  different  ways.  For  example,  
E4orf6 or E1B promote oncogenesis and transformation by inhibiting apoptosis. In 
fact E1B-19K is an analogue of Bcl-2, a potent inhibitor of the Bax pro-apoptotic 
protein family. Eventually, cell cycle deregulation by E1A results in accumulation 
of tumor suppressor p53. In normal circumstances activation of p53 would lead to 
apoptosis but in adenovirus infected cells E1B-55K blocks p53-dependent apoptosis 
by directly binding p53 and impedes expression of pro-apoptotic genes. This viral 
protein also facilitates viral mRNA transportation to the cytoplasm (McConnell, 
Imperiale 2004). A summary of the most important interactions between virus and 
host cell proteins mediating host cell activation to replicate viral DNA massively are 
summarized in table 1 (Berk AJ 2007). 
Proteins  encoded  by  the  E2  genes  are  subdivided  into  those  expressed  by  E2A  
(DNA-binding Protein (DBP) and E2B (pre-terminal protein (pTP) and viral DNA 
polymerase (Pol)). They provide the machinery for viral DNA replication and the 
effective transcription of late genes (Russell 2000).  
E3 genes are dispensable for viral replication but play an important role in avoiding 
host defense mechanisms and enhance persistence in infected cells. One of the E3 
gene products is the Adenovirus Death Protein (ADP) that promotes cell cytolysis 
of the infected cell to force the release of the progeny. Another E3 gene product is 
E3gp19K that prevents loading of peptides onto the MHC class I molecules to be 
presented  on  the  cell  surface,  where  they  would  be  recognized  by  Cytotoxic  T  
Lymphocytes (CTLs) (McConnell, Imperiale 2004). 
The E4 transcription unit encodes for proteins that play a role in cell cycle control 
and transformation by many different mechanisms. For example, E4orf4 estimulates 
p53-dependant apoptosis, while E4orf6 inhibits p53 biding to transcription factors 
and, thus, prevents p53 of inhibiting cell transformation. At the same time, it 
collaborates with E1B-55K to target p53 for degradation. Proteins originated from 
the E4 transcription unit also facilitate virus mRNA metabolism and promote virus 
DNA replication and blockage of host protein synthesis. They also contribute to 
increase resistance to lysis by CTLs (Berk AJ 2007, McConnell, Imperiale 2004, 
Kaplan et al.  1999). Adenovirus also transcribes a set of RNAs, the VA RNAs, that 
are not translated but play a significant role in combating cellular defense 
mechanisms. 
The effects caused by early transcription genes start immediately after infection and 
occur before DNA replication. DNA replication starts from both DNA termini and 
requires both ITRs as origins of replication. After DNA replication, late 
transcription results in a set of five transcription units that express structural 
components of the virus. They are named late transcription genes L1-L5 and 
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operate under the control of the Major Late Promoter (MLP) (Berk AJ 2007). There is 
also  a  peak  of  IVa2  and  IX  gene  expression  and  a  specific  activation  of  the  MLP.  
Although the encapsidation process is not completely defined, it is clear that late 
proteins play a crucial role (McConnell, Imperiale 2004). 
 
1.2.3.5. Assembly 
Although  the  encapsidation  process  is  not  up  to  date,  fully  understood,  it  seems  
clear that formation of a pro-capsid, containing structural and non-structural 
(scaffolding) proteins, is needed, to fully complete DNA packaging. Unfortunately, 
little is known about the structure of this pro-capsid, which has not even been yet 
isolated. The packing sequence ? is responsible for the recognition and 
incorporation of the DNA in the pro-capsid in a ATP-dependant process through an 
opening in the pro-capsid known as the portal. The portal is sealed as soon as the 
DNA is inserted and maturation of the capsid starts. 
A  panel  of  at  least  twelve  viral  proteins  and  the  viral  DNA  are  involved  in  viral  
assembly. Most of the structural proteins are synthesized as longer precursors and 
undergo  processing  by  AP  before  they  are  ready  to  participate  in  viral  
encapsidation. There are several non-structural proteins associated with adenovirus 
assembly  and  maturation  of  the  capsid.  Except  IVa2,  most  of  those  proteins  are  
expressed by the late transcription unit (Ostapchuk, Hearing 2005). 
 
1.2.3.6. Viral release 
While the capsid undergoes maturation process, the nuclear membrane turns more 
permeable and eases the escape of viral particles to the cytoplasm. Finally, the 
Adenoviral Death Protein (ADP), transcribed from the E3 region, forces cell rupture 
and permits viral particle release. As an average, every infected cell releases 10.000 
viral  particles.  The exact  mechanism how adenovirus can lyse  the cell  is  not  clear  
but most evidence points to the important participation of autophagy, a process 
that involves the formation of an autophagosome that fuses with lysosomes which 
triggers caspase activation leading to the destruction of cell structures and cell lysis 
(Jiang et al. 2011). 
 
1.2.4. Immune response to adenovirus infection 
In natural conditions, adenovirus infections would occur from the exterior through 
the epithelial tissue along the respiratory channels or through other epithelia, e.g. 
conjunctiva. Nevertheless, this first barrier is sometimes omitted when adenovirus 
are administered as vectors for gene therapy. In both cases, the immune reaction is 
complex and occurs through several groups of events. Nevertheless, some 
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responses are more important than others depending on the route the virus uses to 
access the body. This section will be focused on the most influential immune 
reactions caused by adenovirus. 
 
1.2.4.1. Innate immune response 
The innate immune response constitutes the first defense of the immune system 
against adenovirus infection. It is initiated by interaction between the host cell and 
the virus and is independent of gene transcription. The innate immune system 
involves a highly complex network, with high levels of redundancy but also cell-
level specificity. In addition, many external factors increase its diversity of effects.  
Special attention will be paid to two of the most influential mechanisms of the 
innate immunity to adenovirus: the interferon ? receptor (IFN-? receptor) and 
interleukin-1 (IL-1) receptor pathways (Thaci et al. 2011). 
The interleukin-inflammatory pathway 
The interleukin-inflamatory pathway leads to the recruitment of pro-inflammatory 
infiltrate aimed to eliminate the pathogen. Even if an early recognition of the virus 
can already activate an immature form of IL-1, the maximum inflammatory 
response is based on a fully-functional IL-1R. Downstream events of IL-1R 
activation  lead  to  the  induction  of  NF-?B,  a  transcription  factor  that  triggers  the  
expression of chemokines in the nucleus, including IL-1(Thaci et al. 2011). 
The earliest cell sensor that gets activated upon viral infection is the interaction of 
CAR with the fiber protein (Tamanini et al. 2006). However, opinions are divided 
and some authors claim that RGD interaction with ??-integrins is indeed the first 
event inducing innate immune response. In any case, both interaction coincide with 
the NF-?B mediated expression of chemokines (Russell 2009, Thaci et al. 2011). 
The intensity of later events in the innate immune response depends on the 
efficiency of the virus to escape from the endosome and, consecutively, the amount 
of viral DNA in the cytosol. But prior to that, double-stranded DNA present inside 
the endosome is already detected by several cell receptors: toll-like receptors (TLR), 
especially TLR9, DNA-dependent activators of IFN-regulatory factors (DAI) and/or 
nucleotide oligomerization domain (NOD)-like receptors (NLRs). Downstream 
effectors of the immune response will depend on which pathway becomes activated 
(Russell 2009, Thaci et al. 2011). For example, TLR9 activation induces maturation of 
pro-IL-1? in macrophages that is dependent on a cytosolic innate molecular 
complex known as the “inflammasome”. Activation of caspase-1 is needed for the 
formation of this complex (Barlan, Danthi & Wiethoff 2011, Muruve et al. 2008). 
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Interferon response 
Three groups of IFNs have been identified according to the receptor they recognize. 
Type I includes IFN-? and ? that signal through the IFN-AR receptor. Type II IFNs 
are secreted by lymphocytes in response to pathogen antigens during adaptive 
immune  response  and  type  III  IFNs  are  not  well  characterized  (Meyer  2009,  
Levraud et al.  2007). Induction of type I IFNs is responsible for NK cell activation 
and regulation of the innate immune response against  adenovirus (Zhu, Huang & 
Yang 2008). Adenovirus-mediated IFN responses are partly induced by recognition 
of foreign nucleic acid. Interaction of adenovirus with cell surface receptors does 
not cause induction of IFNs (Thaci et al. 2011). Endosomal TLR9 recognizes CpG-
rich viral DNA and activates plasmacytoid dendritic cells (pDC) that lead to the 
secretion  of  IFN-? through  the  MyD88-dependent  pathway.  In  reality,  a  complex  
interplay between the IFN and inflammatory pathways are needed to clear 
adenovirus infections completely (Thaci et al. 2011).  
 
1.2.4.2.  Adapted immune response 
The innate immune response is responsible for initiation of the adaptive response 
and modulates  its  progression.  In  order  to  start  the adaptive response,  adenoviral  
antigens must be presented to cytotoxic T-cells by dendritic cells and macrophages. 
In contrast to the innate response, the adaptive immune response requires B and T 
cell maturation and function, and takes approximately one week to become 
effective. The mechanism of elimination of adenovirus through the adapted 
immune response is similar to the removal of other antigens (Zaiss, Machado & 
Herschman 2009; Russell 2000).  
Intracellular antigens are presented to CD8+ cytotoxic cells (CTL) through the MHC 
class  I.  On  the  other  hand,  antigens  in  the  viral  capsid  are  presented  through  a  
MHC class II to CD4+ helper cells. While CTL produce lysis of the infected cell, 
helper cells trigger a B cell proliferative response against the infection. This 
provides the amount of immunoglobulines needed for the humoral response (Zaiss, 
Machado & Herschman 2009; Russell 2000).  
Adenoviruses combat the CTL response with E319K protein that retains the MHC 
class I in the ER and impedes its translocation to the cell surface to complete antigen 
presentation (Fu, Li & Bouvier 2011). In parallel, E4 gene products inhibit cytolysis 
by T cells (Kaplan et al. 1999). 
The humoral response 
The humoral response is the major component for the host cell defense towards 
adenoviral infections and is based on the production of surface immunoglobulins 
by B cells  that  recognize a  certain adenoviral  antigen.  This  first  recognition of  the 
antigen initiates an industrial proliferation of T helper cells (CD4+) accompanied by 
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the release of immunoglobulins against the antigen. We will refer to those 
immunoglobulins as adenovirus neutralizing antibodies (Russell 2000). 
Neutralizing antibodies are directed against the hexon and other capsid proteins, 
fiber and penton. In the hexon, the epitopes are located in the hyper-variable region 
(HVR) that is the least conserved part of the protein. The recognition of the capsid 
epitopes by different neutralizing antibodies permitted the classification of 
adenovirus in their 51 different serotypes (Russell 2000).  
 
1.3. HUMAN DISEASES CAUSED BY ADENOVIRUS 
Adenoviruses are, in general, species specific. Excluding very few exceptions, 
humans and animals  are  not  susceptible  to  pathogenicity  by the same adenovirus 
serotypes. However, some adenoviruses cause non-symptomatic infections in 
humans and in animals that can be detected by presence of antibodies. Among 
children, the most usual route of transmission is feco-oral which is facilitated by 
adenovirus accumulation into faces due to the prolonged carriage of the virus in the 
intestines.  However,  the  spread  can  also  occur  through  the  respiratory  track.  The  
epidemiologic significance of the long latency in tonsil tissue is still unknown 
(Wold S.M. 2007).  
Although symptomatic adenovirus infections can occur many times during the life 
of a human being, they rarely become persistent. It is estimated that adenoviruses 
are present only in 3% of the asymptomatic civilian population, and in 7% of the 
cases of patients that present febrile symptoms. Among children, prevalence is 5 %, 
and 10 % in the case when the children are presenting febrile symptoms (Wold S.M. 
2007). A recent study detected adenovirus in fecal samples of 3,6 % of children 
hospitalized with symptoms of gastroenteritis (Andreasi et al. 2008) and another 
study found adenovirus particles in 2 – 9 % (depending on the screening method) of 
autopsies from pediatric patients of fatal pneumonia (Ou et al. 2008). Still, serologic 
surveys  show  that  antibodies  to  Ad1,  2  and  5  are  present  in  40-60  %  of  children.  
Although adenovirus infections are not related to particular habits, during the 
outbreaks of adenoviral infection in military recruits during World War II, factors 
such  as  fatigue  due  to  everyday  training,  the  winter  season  and  congregation  of  
people sleeping together were considered to increase the infection (Wold S.M. 
2007). Similarly, a recent study showed that adenoviral conjunctivitis in children 
clustered around environments with congregation of children, like daycare centers 
(Adlhoch et al. 2010). 
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Table 2: Diseases associated with adenovirus infections (Wold S.M. 2007) 
Disease 
Main 
serotypes 
Individuals at higher 
risk 
Symptoms Prognosis 
Acute febrile 
pharyngitis 
1, 2, 5, 6, 
(3, 7) 
Children < 5 years old 
Local: Nasal congestion, 
coryza, cough. 
Systemic: malaise, fever, 
chills, myalgia, headache 
 
Pharyngocon
junctival 
fever 
3, 7, 14 Children 
Same as above plus 
conjunctivitis 
 
Acute 
respiratory 
disease 
(ARD) 
4, 7, (3) 
Military recruits. Risk 
factor: fatigue and 
crowding 
Fever, respiratory 
symptoms, cough, sore 
throat, pneumonia (Kajon 
et al. 2010) 
Some cases: 
death due to 
pneumonitis 
Pneumonia 
(children) 
1-3, 7 Infants, young children   
Pneumonia 
(adults) 
4, 7 Military recruits   
Pertussis-like 
syndrome 
5 Infants, young children 
Clinical whooping cough 
(together with other causal 
agent) 
 
Eye 
infections 
1-4, 6,7,9-
11,15-17, 
20, 22 
 
Mild symptoms of 
conjunctivitis 
Complete recovery 
is most usual 
Epidemic 
keratoconjun
ctivitis 
8, 11, 19, 
37 
Children and adults 
Follicular conjunctivitis, 
eyelid edema, pain, 
lacrimation, photophobia, 
(corneal opacity) 
Some cases: 
corneal opacities 
lasting for years; 
or progression to 
hemorrhagic 
conjunctivitis 
Acute 
hemorrhagic 
cystitis 
11, (21) 
Young children, mostly 
males 
Hematuria 
Self-limited 
disease 
Meningoence
phalitis 
7, 12, 32 
Children, 
immunocompromised 
hosts 
  
Gastroenteriti
s 
40, 41 Infants, young children   
Hepatitis 1, 2, 5 
Infants and children 
with liver transplants 
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The most common sites of Adenovirus infection and replication are the respiratory 
track, eye and gastrointestinal track. Less frequent sites are the urinary bladder and 
the liver.  Very seldom, infections of  other  organs have been reported,  such as  the 
pancreas, myocardium or central nervous system.  
Normally the association between adenovirus and disease is attributed to virus or 
antibodies detection in blood or in a specific tissue. However, the sole presence of 
the  virus  or  viral  DNA  in  a  tissue   is  not  enough  to  confirm  association  with  the  
symptoms,  since   adenovirus  can  persist  at  very  low  levels  in  humans  for  a  long  
time (Wold S.M. 2007). Table 2 summarized the most relevant diseases caused 
directly by adenoviruses (Wold S.M. 2007). 
 
 
 
 
Figure 7: Anatomy of the hexagonal lobules in the liver 
The liver is divided into hexagonal functional units called lobuli, which are separated from each other by 
portal triads that consist of branches of the bile duct, portal vein and hepatic artery. The portal triad and 
the interlobular veins are connected are in the center of the hexagonal lobules. They carry blood to the 
hepatic vein, through the sinusoids. Adapted from Benjamin Cummings (2001) 
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1.4. ADENOVIRUSES AS BIOLOGICAL DRUGS FOR THE TREATMENT OF 
CANCER 
Adenovirus vectors are normally delivered to the organism through completely 
different routes than in naturally occurring infections. In animal models, the 
persistence of adenoviral particles in the  blood after intravenous administration is 
lower than 2 minutes (Alemany, Suzuki & Curiel 2000) due to rapid sequestration to 
multiple organs including the spleen, heart, lung and specially the liver. However, 
transgene  expression  occurs  mainly  in  hepatocytes.   Clinical  human  data  on  
adenovirus  pharmacokinetics  /  pharmacodynamics  is  rather  limited.  However,  a  
biodistribution  study  of  one  patient  who  died  due  to  cancer  progression  after  
adenoviral treatment, established that after 56 hours, nearly all adenovirus particles 
had disappeared from the blood and were retained in spleen and liver hepatocytes 
(Alemany 2007). This retention of viral particles by liver tissue represents two major 
obstacles for vector delivery: the decrease in the fraction of dose effectively delivered 
to target tissue (e.g. tumor) and the potential toxic effects in the liver (Zaiss, 
Machado & Herschman 2009). Liver toxicity by adenovirus starts with an acute 
inflammatory response caused by a rapid induction of pro-inflammatory cytokine 
and chemokine expression. This leads to massive leukocyte infiltration that results in 
necrosis and tissue damage. Hepatotoxicity caused by adenovirus is dose-dependent 
but non-related to viral gene expression which means that the viral capsid by itself is 
capable of  inducing an innate immune reaction (Muruve et al. 1999) 
The liver is divided into hexagonal functional units called lobuli (figure 7). A lobul is 
separated from its neighbor by portal triads that consist of branches of the bile duct, 
portal vein and hepatic artery. The portal triad is connected to the interlobular veins 
that are located in the center of the hexagonal lobulus and carry blood to the hepatic 
vein, through the sinusoids. Cells in the sinusoids are a compilation of endothelial 
cells (70% of sinusoid cells), Kupffer cells (20%), fat-storing cells (or stellate cells; 
10%)) and pit cells (NK cells; <1%). All these constitute 33 % of the number of cells 
resident in the liver, the rest is occupied by liver parenchymal cells, i.e. hepatocytes 
(Jacobs, Wisse & De Geest 2010). After systemic administration, adenoviral vectors 
enter the liver through the sinusoids. Precisely, fenestrae in the liver sinusoid 
endothelial cells, provide direct access for the adenovirus to the liver parenchyma, 
that  occurs  through  the  space  of  Disse,  located  between  the  sinusoid  cells  and  
hepatocytes. Since Kupffer cells are also present, it is at this point when the 
adenovirus gets in contact with them. (Jacobs, Wisse & De Geest 2010; 
Shayakhmetov et al. 2004) (Figure 8). Indeed, the diameter of fenestrae is the main 
determinant of adenovirus sequestration by the liver. Gene therapy vectors based on 
other viruses with larger particle size (e.g. lentiviral vectors) feature lower 
transduction to hepatocytes (Follenzi et al. 2002). At the same time, liver infection 
with adenovirus vectors is significantly more effective in animal species with larger 
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fenestrae (Lievens et al. 2004, Wisse et al. 2008, Follenzi et al. 2002, Follenzi et al. 
2002). 
Kupffer cells are specialized macrophages, located in the liver, that belong to the 
reticuloendothelial system (RES) that  phagocityze adenoviral particles and activate 
innate immune response against them. Adenovirus uptake by Kupffer cells, which 
is  not  dependant  on  CAR,  presents  a  threshold  dose.  Under  this  dose,  almost  all  
adenovirus particles are sequestered by Kupffer cells whereas above it, Kupffer 
cells get saturated and viral particles are available to target other cell types 
(Shayakhmetov et al. 2004). In mice, the threshold dose is 3x1010 viral particles. This 
dose is very important to design experimental protocols for in vivo experimentation 
(Tao et al. 2001). According to some studies, sinusoid epithelial cells would be the 
next cell type to interact directly with adenovirus (Liu et al. 2003) . 
The biodistribution pattern of Ad5 urges the need to obtain vectors with modified 
tropism in order to increase their persistence in circulation and achieve a reasonable 
distribution to the target organ. Gene therapy for cancer faces also the problem of 
tumor cells presenting a differential pattern of surface membrane proteins, for 
example lower amount of CAR than normal cells. Designing viral particles with 
increased affinity to those proteins expressed exclusively in tumor cells (tumor 
targeting) and modifying the adenovirus particle to avoid infection of liver cells 
(liver  de-targeting)  are  the  two  major  goals  of  cancer  gene  therapy.  Most  of  the  
work presented in this thesis explores these issues. 
 
 
Figure 8: Anatomy of the liver sinusoid 
The sinusoid is surrounded by a fenestrated layer of endothelial cells. This layer is separated from the 
hepatocytes by the space of Disse. The Kupffer cells are located on the external surface of the 
endothelial cells (Follenzi et al. 2002). Adapted from Liver Int. © 2005. Blackwell Publishing 
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During the last decades, many novel modifications have been applied to adenovirus 
in order to control their tropism and maximize the selective delivery of viral DNA 
to the target cells. Owing to the large amount and complexity of adenovirus vector 
types, any attempt to arrange them in a simple classification would run the risk of 
becoming over-simplistic. Nevertheless, general trends or groups of vectors will be 
classified and described according to two different criteria: the stage of viral 
infection / replication aimed to modify and the final effect the vector is designed to 
achieve. 
 
1.4.1. Adenovirus vectors according to the type of modification 
A common requirement for all adenovirus vectors is the need to control their 
tropism. In the case of cancer, the ideal vector should only be capable of infecting 
and/or replicating in tumor cells, leaving normal cells unharmed. Modifications 
can be made in the protein capsid or viral genome in order to control some of the 
steps of  infection.  Depending on which stage is  altered,  adenoviral  vectors  can be 
classified as described in this section.  
 
1.4.1.1. Transcriptional targeting 
Transcriptional modifications interfere with the normal expression of adenoviral 
genes  at  the  level  of  transcription.  Suppression  of  certain  transcripts  can  be  
conditional or constitutive. Most common methods to alter normal adenovirus 
transcription are the following: 
Genetic deletions 
Deletions of the adenoviral genome have been extensively used in order to restrict 
viral replication or expression of an artificially-inserted transcript to some specific 
context (e.g. tumor cells). An important impediment to develop replication 
competent vectors that conditionally replicate in cancer cells is that effective 
adenovirus replication requires the participation of most adenoviral genes. For that 
reason, genetic deletions must be very selective and precise to preserve the 
replication machinery. Therefore, instead of removing entire regions of the genome, 
deletions of small genes or of particular exomic sequences in the genome have been 
commonly utilized.  A well-known example is the mutant vector dl1520 or Onyx-
015.  It  was  used  in  clinical  trials  and  consists  of  an  adenovirus  serotype  5  vector  
where E1B-55 kDa gene is deleted. This gene confers conditional replication in p53-
deficient cells (Nemunaitis et al. 2001, Ganly et al. 2000). Another sequence scission 
commonly found in the literature is the 24-bp deletion (?24) in region CR2 of E1A 
that  impairs  E1A  protein  to  bind  Rb  protein  and,  hence,  the  release  of  E2F  
transcription factor.  As a  consequence,  the virus  can only replicate  in  cells  with a  
defective p16/Rb pathway (Fueyo et al. 2000, Heise et al. 2000).  
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On  the  contrary,  when  viral  replication  is  to  be  ablated  in  any  cell  type,  larger  
regions of  the genome can be omitted,  giving room to additional  benefits,  such as  
the capacity of inserting larger transgenes. The development of new replication-
incompetent adenoviral vectors evidenced how blurry the idea of “essential regions 
for viral replication” truly is. Even the so-called “first generation vectors” where E1 
and/or E3 regions have been totally or partially removed, still show minimal 
production of replication-competent particles in vivo, especially at high MOIs 
(Russell 2000, McConnell, Imperiale 2004, Stone et al. 2000, Hoff, Margetts 2006). 
Therefore, “second generation vectors” featured partial or total deletion of genes in 
the E2 region.  Those regions express  genes  important  for  viral  replication such as  
polymerase or the pre-terminal protein (Berk AJ 2007). The “third generation 
vectors” consist of adenoviruses where additional genes have been deleted, and this 
group includes the “gutless” vectors (see figure 9 for a schematic representation of 
the different groups of vectors with impaired replication due to gene deletions) 
(Russell 2000, Hoff, Margetts 2006; McConnell, Imperiale 2004; Stone et al. 2000). 
These  vectors  go  to  the  extreme  in  including  only  the  ITRs  and  the  packing  
sequence. Replication is only possible with aid of a helper virus (Alba, Bosch & 
Chillon 2005) (See figure 9). 
 
 
 
Figure 9: Classification of transcriptionally modified non-replicating vectors using gene deletions into 
so-called “vector generations” 
First generation vectors comprise those with total or partial deletion of E1 and/or E3 genes. Second 
generation vectors add a partial or total deletion of genes in the E2 region that express important genes for 
viral replication as polymerase or the pre-terminal protein. The third generation vectors consist on 
adenoviruses where additional genes have been deleted. Modified from Hoff et al., 2006 
 
Specific promoters or control on promoter expression 
Specific promoters can be used to drive the expression of genes under specific 
conditions. Those selectively-expressed genes would include artificially inserted 
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transgenes, one example is the expression of thymidin kinase driven by the 
hypoxia-inducible promoter in cancer cells (Harvey et al. 2011) or the expression of 
luciferase transgene driven by survivin promoter (Zhu et al. 2004). Essential genes 
for  replication can also be conditioned to  a  specific  context,  like  in  the case  of  the 
conditional  replication  adenovirus  where  the  E1A  gene  is  driven  by   the  wnt  
promoter (Liu et al. 2011).  
 
1.4.1.2. Transductional targeting 
Transductional targeting comprises of all those modifications based on promoting 
or ablating certain viron-cell interactions in order to change viral tropism. This 
includes strategies  such as  molecular  mutation of  hexon,  fiber  or  penton proteins,  
substitution of capsid proteins for other serotypes or the incorporation of ligands to 
the capsid proteins. Capsids or certain proteins of the capsid can also be coated 
with polymers in order to change tropism directly or by helping the virus to escape 
from the humoral immune response (Hedley et al. 2006, Kreppel, Kochanek 2008). 
 
1.4.1.3. Translational targeting 
Translational targeting is focused on modifying the viral transcriptome in order to 
achieve selective translation of genes according to the cell type. This means that, even if 
the transcriptome is similar as with wild type virus, certain genes are selectively 
translated  under  defined  conditions.  This  can  be  achieved  by  the  use  of  RNA  
technology, and particularly micro RNA (miRNA) systems (Sakurai, Katayama & 
Mizuguchi 2011; Edge et al. 2008, Barnes et al. 2008; Kelly et al. 2008). miRNA are 
single-stranded RNA molecules of 21-23 nucleotides in length, that regulate gene 
expression.  Although  miRNAs  are  transcribed  from  genomic  DNA,  they  are  not  
translated into protein. Mature miRNA molecules are partially complementary to one 
or  more  messenger  RNA  (mRNA)  sequences,  and  their  main  function  is  to  down-
regulate gene expression (Ambros 2001, Moss 2002). 
The  most  used  method  of  translational  targeting  is  the  insertion  of  miRNA  
complementary binding sequences to the 3’UTR of the gene or transcript that is to be 
selectively expressed. This results in the silencing of the target gene when the miRNA is 
present in the infected cell. One example of this is the insertion of liver specific miRNA 
binding sequences in order to ablate replication (Ylosmaki et al. 2008) or transcript 
expression (Suzuki et al. 2008) in liver cells.  
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1.4.2. Adenovirus vectors according to the final effect on host cells  
1.4.2.1. Oncolytic adenovirus 
Oncolytic  adenoviruses  complete  their  lytic  life  cycle  in  the  host  cell.  As  a  
consequence,  oncolytic  adenoviruses  replicate  as  well  as  destroy the host  cell  and 
release the progenies to the extracellular compartment. The release of new viral 
particles (10.000 viral particles per cell infected on average) is the basis of the self-
amplifying effect of oncolytic adenovirus-based treatments (Kay, Glorioso & 
Naldini 2001). Oncolytic adenoviruses are designed to selectively replicate in cancer 
cells while leaving normal cells unharmed.  
 
1.4.2.2. Armed (transgene-expressing) adenovirus 
Adenoviruses are transient expression vectors that allow efficient delivery of 
genetic material but, unfortunately, cannot accommodate large transgenes. It is 
estimated that they cannot increase their genome more than 5%, so they can only 
incorporate a maximum of 2 kb of “extra” DNA (Cody, Douglas 2009).  A larger 
increase in genome size rises the likelihood of genome packaging mistakes and 
impedes proper viral assembly. Therefore, non-essential regions must be eliminated 
before insertion of large DNA trangenes. What regions are essential depends on the 
used vector, and especially on whether a replicating or non-replicating vector is 
expected. For the design of non-replicating vectors, most frequent regions to be 
complete or partially substituted are E1 and E3 (Russell 2000, McConnell, Imperiale 
2004; Stone et al. 2000). The most frequently used groups of transgenes used for the 
treatment of cancer are those that directly enhance cancer cell killing and those that 
indirectly enhance cell killing by modulating the tumor microenvironment. A third 
group  would  be  those  transgenes  that  stimulate  an  immune  response  against  the  
tumor(Cody, Douglas 2009). 
Transgenes that enhance cell killing 
Use of certain transgenes can ultimately enhance cell killing by the adenovirus by 
improving selectivity towards cancer cells. These type of transgenes act at three 
different levels: within the infected cell, through a bystander effect or by increasing 
viral spread (Cody, Douglas 2009). The first group improves the destruction of the 
host cell by a mechanism independent of direct viral oncolysis but restricted to the 
cell the virus is infecting. Such an oncolytic effect can be obtained by silencing of 
particular  cell  essential  genes  using antisense cDNAs (Gao et  al.  2006,  Zhou et  al.  
2005), small-interfering RNA (siRNA) (Zhang et al. 2006) or genes that stimulate 
apoptosis of the infected cell (Gao et al. 2006, Zhou et al. 2005, Cui et al. 2008). 
However,  restricting  the  killing  of  the  infected  cell,  as  safe  as  it  might  seem  in  
principle, implies an important limitation to reach a generalized elimination of the 
tumor  tissue.  To  avoid  this,  the  so-called  suicide  genes  are  expressed  only  in  
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infected cells but are also lethal for neighboring, non-infected cells through a 
collateral effect. Gene products of suicide genes are pro-drug converting enzymes 
that turn non-toxic pro-drugs into toxic metabolites. Two of the earliest 
enzyme/pro-drugs combinations that were used were herpes simplex virus 
thymidine kinase / gancyclovir (HSV-TK / GCV) and the cytosine deaminase / 5-
fluorocytosine (CD / 5-FC). Other options for cell killing are strategies that enhance 
viral spread. This can be achieved by reinforcing the lytic phase of the virus by 
over-expression of ADP. In practice, ADP is inserted into an “extra” region (e.g. E3 
region (Tollefson et al.  1996, Doronin et al.  2000)) or under the control of a foreign 
promoter, more potent than MLP (e.g. CMV(Yun et al. 2005)). Tumor necrosis factor 
(TNF)-related apoptosis-inducing ligand (TRAIL) is another promising transgene 
that has shown to enhance viral spread without toxicity in vivo (Sova et al. 2004). 
Transgenes that modulate the tumor microenvironment 
The tumor microenvironment has emerged as an important factor in cancer 
development and as a key determinant of the disease outcome. Most transgenes 
aimed to modulate the tumor microenvironment are divided into those that target 
the ECM and those that inhibit angiogenesis (Cody, Douglas 2009). Within the first 
group, contradictory results have been presented. Several authors have expressed 
metalloproteinase (MMP) inhibitors, such as TIMP3 (Lamfers et al. 2005), in order to 
reduce proteolysis of the ECM and basement membrane components to achieve 
superior tumor invasiveness suppression. However, other authors showed how 
expressing ECM-degrading proteases bear the benefit of increasing tumor 
spreading of the gene therapy vector (Ganesh et al. 2007, Kim et al. 2006). This 
second approach is more broadly discussed in the section 1.7.1. 
A second group of  tumor microenvironment modulating transgenes would consist 
of those that are aimed to inhibit angiogenesis. Examples include endostatin (Fang 
et al. 2010) or Flt1 that blocks angiongenesis by inhibition of vascular endothelial 
growth factor (VEGF) (Zhang et al. 2005), short-hairpin RNAs (shRNA) directed 
against VEGF (Yoo et al. 2007) and expression of a zinc-finger protein targeted 
against VEGF promoter (Kang et al. 2008). 
Immunomodulatory transgenes 
A third group of transgenes are used to stimulate the immune system, generally by 
recruitment of immune cells to the site of infection and subsequent induction of 
their proliferation and activation. Recruitment of immune cells to the primary 
tumor not only has the potential to directly destroy it but also to impede metastatic 
progression and recurrence (Cody, Douglas 2009). In this regard, GM-CSF encoding 
adenoviruses have been shown to improve oncolytic potency of intratumorally 
injected replicating vectors (Burke 2010). This effect was multiplied when the virus 
expressed the T-cell co-stimularory molecule B7-1 (Choi et al. 2006). Other 
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immunity mediators that have been co-expressed by adenovirus, are TNF-? that 
increases MHC class I expression, IFNs or interleukins like IL-4 and IL-12. Of 
special mention is the strategy of co-expressing the so-called heat shock proteins. 
These proteins act as chaperones for antigen-presenting cells, so they trigger 
antitumor response and activate several immune cells (Guo, Fang 2008). 
 
1.5. COLORECTAL CANCER 
Colorectal  cancer  (CoCa)  is  driven by the development  of  a  primary tumor in  the 
colon, rectum or vermiform appendix. While tumors confined within the colon wall 
are often curable with surgery, cancers that have spread widely around the body 
are normally not curable and lead to a survival of less than 5 years (Coleman et al. 
2008, Center, Jemal & Ward 2009). Colorectal cancer is the fourth most common 
type of cancer in men and the third most common in women worldwide. More than 
one million people are diagnosed with colorectal cancer every year. Prognosis rates 
have  improved  in  the  last  decades  and  vary  among  countries.  In  Europe,  5-year  
survival accounts for 70 – 79% while in Finland, Sweden, North America, Australia 
and Japan it  goes  up to  80% of  the patients  (Coleman et  al.  2008,  Center,  Jemal  & 
Ward 2009). Early diagnostic is essential for a good prognosis. Metastatic disease 
represents the most aggressive form of the disease, in fact even lesions that undergo 
curative  resection  lead  to  a  survival  higher  than  5  years  in  50%  of  patients.  Most  
common locations for metastases are the liver, followed by the lungs and peritoneal 
wall (Simmonds et al. 2006). 
Typical risk factors for CoCa are advanced age (Patel et al. 2009), personal and 
family history of cancer (Gala, Chung 2011), polyps in the colon, smoking (Office of 
the Surgeon General (US), Office on Smoking and Health (US) 2004), a diet rich in 
red  meat  and  poor  in  vegetables  and  fresh  fruit  (Corpet  2011,  Aune  et  al.  2011),  
obesity and/or physical inactivity (Calle et al. 2003),  excessive alcohol consumption 
(Cho et al. 2004) and low vitamin B6 intake (Le Marchand et al. 2011). CoCa may 
cause  several  symptoms  that  are  not  specific  of  the  disease,  such  as   change  in  
bowel habits, blood (either red or dark) in the stool, diarrhea, constipation, feeling 
that the bowel does not empty completely, narrower stools than usual, frequent gas 
pains, bloating, fullness, abdominal cramps, weight loss for no known reason, 
asthenia or vomiting. 
Diagnostic of CoCa is based on the results from colonoscopy or sigmoidoscopy with 
tumor biopsy.  In  order  to  decide a  treatment  strategy,  it  is  necessary to  assess  the 
stage of the cancer. This is done by physical examination, a complete colonoscopy 
and  computerized  tomography  (CT)  of  the  chest,  abdomen  and  pelvis  to  identify  
possible metastatic disease. In particular, CT is very useful for establishing the 
specific localization of the tumors. In the case of rectal cancer, it is crucial to define 
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the tumor extension and depth of invasion in the bowel wall and, for that, high-
resolution MRI and ultrasounds are particularly useful. The presence and extent of 
the possible metastatic disease is determined by ultrasound, CT and MRI 
(Cunningham et al. 2010).   
The most common colon cancer cell type is adenocarcinoma (95% of cases), 
followed by lymphoma and squamous cell carcinoma. Since adenocarcinomas are 
malignant tumors, they eventually invade the colorectal wall. Thereby, tumors are 
classified according to the level of penetration and dissemination/invasion to other 
tissues. The most common classification is the TNM (tumors/nodes/metastases) 
system from the American Joint Committee of Cancer (AJCC). Other classifications 
are the Dukes system or Astler-Coller system.  
The staging of the tumors and the physical condition of the patient are the variables 
used to decide a treatment modality. Surgery is a common management option and 
can be curative when the tumor is localized and has not invaded other tissues. It is 
applied to colon tumors by total resection of the tumor and its margins. In parallel, 
lymphadenectomy is performed in order to establish nodal staging by histological 
analyses of the explants. In the case of rectal cancer, complete local excision or total 
excision of the mesorectum is performed together with lymphadenectomy. Risk of 
lymph-node involvement is associated with the depth of tumor invasion in the 
rectal wall. Laparoscopic colectomy is used for colon cancer, especially for left-sided 
cancers,  and  shows  similar  long-term  recurrence  rates.  Surgery  is  also  used  with  
some lung and liver metastases in combination with chemotherapy (oxaliplatin) 
given before and after tissue removal. Some unresectable liver metastases can 
become resectable after chemotherapy treatment if the response to the drug is good. 
Radiation  therapy  is  commonly  used,  as  an  adjuvant  to  surgery,  to  treat  highly  
invasive  tumors.  Chemotherapy  can  be  used  with  two  different  goals:  as  an  
adjuvant  to  surgery  or  as  the  primary  therapy.  When  used  as  an  adjuvant,  drugs  
selected are normally 5-fluorouracil, leucovorin, irinotecan or oxaliplatin. On the 
other  hand,  as  a  treatment  for  the  metastatic  disease,  combination  of  several  
chemotherapeutics are most frequent, e.g. 5-fluorouracil, leucovorin and 
oxaliplatin, (FOLFOX). Other therapeutical strategies are also possible, like 
radiation therapy or monoclonal antibodies (especially bevacizumab or anti-EGFR 
monoclonal antibodies) (Cunningham et al. 2010).  
At  the  molecular  level,  colorectal  cancer  is  driven  by  the  transformation  and  
progression of normal colonic epithelial cells to cancer cells through a mechanism 
based on the accumulation of genetic and epigenetic alterations. This process,that 
takes from 8 to 12 years, is caused by the activation of oncogenes and inactivation of 
tumor suppressor genes by specific mutations. It is estimated that for the entire 
process to be completed, at least 4-5 genes have to be mutated, but the order how 
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those mutations occur is not important. When the mutation affects a tumor 
suppressor gene, a biological effect is produced even if the mutation is present in 
the heterozygote state, (Fearon, Vogelstein 1990; Saif, Chu 2010). Most important 
steps in this genetic model for CoCa are represented in figure 10. 
 
 
Figure 10: Genetic model for colorectal cancer 
The genetic model defines the progression of the normal colon epithelium to carcinoma cells as a 
multistep process that five levels of cell differentiation. The progression from one level to the next 
depends on several genetic and epigenetic events, some of the most important are included in the 
figure (Fearon, Vogelstein 1990, Saif, Chu 2010). 
 
 
According  to  their  etiology,  CoCa  can  be  divided  into  sporadic  or  hereditary.  
Sporadic or non-hereditary CoCa accounts for 80 to 85% of the cases, while 
hereditary  CoCa  occurs  in  8  to  15%  of  the  patients.  The  two  major  forms  of  
hereditary CoCa are familiar adenomatous polyposis (1-2%), caused by genetic 
mutations  in  the  adenomatous  polyposis  coli  (APC)  gene,  and  hereditary  
nonpolyposis CoCa (around 5%), which arises from genetic mutations in the family 
of mismatch repair genes. Interestingly, similar genetic alterations as those found in 
hereditary CoCa have been implicated in the development of sporadic CoCa. These 
alterations include the Wnt/?-catenin, TGF-? receptor, Notch and hedgehog 
signaling pathways. Besides, other signaling pathways, crucial for colonic epithelial 
cell growth mediation, include the epidermal growth factor receptor (EGFR), the 
RAS/RAF/MAPK cascade and the phosphoinositide 3’-kinase (PI3K)/Akt 
pathway. All these altered signalling pathways offer many possible targets for 
rational drug design (Saif, Chu 2010). 
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1.6. MURINE MODELS OF CANCER 
The optimal animal model for assessing activity of a potential new anti-tumor drug 
is  usually  a  cause  of  controversy  among  researchers.  The  reason  for  that  is  the  
scarce predictive power of the traditional in vivo tumor models to foretell how 
humans will respond to the treatment in the future. This is not common in some 
other  pharmacological  areas,  where  a  positive  response  to  the  drug  in  animal  
models is followed by a positive response in humans (e.g. antifungal drugs). In any 
case, in vivo models generally represent a more relevant platform for drug testing 
compared to many other systems like in vitro models (Cespedes et al. 2007). A brief 
introduction to the most common types of in vivo models will be further described. 
Xenograft models of colorectal cancer will be emphasized in order to introduce the 
research topics described later in this Doctoral Thesis. 
 
1.6.1. Syngeneic models  
In syngeneic models, mice bear tumors originated from individuals belonging to 
their own species or strains. The tumors are induced initially by chemical or 
surgical intervention and material from the primary tumor (tissue explants or cells) 
is introduced to naïve members of the same mouse strain. Syngeneic models have a 
relative low cost and are reproducible regarding tumor histology and tumor growth 
rate. Besides, the stroma-cancer cell interactions are well preserved. Furthermore, 
tumor implantation is not immunogenic, so fully immunologically competent mice 
can be used. Unfortunately, in many cases, target cells or tissues present significant 
differences to human ones, which represents an important limitation (de Jong, 
Maina 2010). 
 
1.6.2. Xenogeneic models 
Xenogeneic models are constructed by implantation of material from a human 
tumor  into  an  immunosupressed  host.  Indeed  most  xenograft  models  are  not  
compatible with a fully functional immune system that would reject implanted 
cells. For that reason, most used experimental xenogeneic models are based on 
genetically manipulated athymic mice (nu/nu) (i.e. they lack the thymus and, 
hence, are unable to produce T cells) or severe combined immunodeficiency mice 
(SCID)  that  lack  both  humoral  and  cellular  immune  components.  In  any  case,  
tumors of human origin in xenogeneic models are better predictors of drug efficacy 
in humans than murine tumors in syngeneic models. Also, they count with a broad 
pool of well-characterized cell lines, therapeutic targets are homolog and they are 
highly reproducible. The main drawback is that the tumor mass consists of cells 
derived from two species: cancer cells of human origin in murine-derived stroma. 
This may lead to discrepancies in tumor histology and intra- and peritumoral 
vasculature as a result of altered interaction patterns between those elements (de 
Jong, Maina 2010).  
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Xenogeneic  and  syngeneic  models  can  be  divided  according  to  the  site  of  tumor  
implantation. Thus, we define orthotopic models as those where the tumor material 
is  implanted  at  the  site  of  the  primary  tumor  source,  while  in  non-orthotopic  
models tumor material is implanted in a different location, normally 
subcutaneously (de Jong, Maina 2010; Sausville, Burger 2006). 
 
1.6.2.1. Metastatic xenogeneic models of colorectal cancer 
Metastatic  progression,  normally  to  the  liver  but  also  to  lungs  or  peritoneum,  
represents the most aggressive consequence of colorectal cancer. The metastatic 
process includes primary tumor implantation, cell migration, release to blood flow, 
survival in blood stream / lymphatic vessels, invasion of vessel wall, migration to 
target organ, colonization and tumor tissue development (Peeters et al. 2008). 
Because  metastases  is  such  a  complex  event,  few  in vitro or in vivo models can 
mimic all the processes and normally they just reproduce one of few stages (Makale 
2007, de Jong et al. 2009). 
For the in vivo study of human metastatic colorectal cancer, xenograft models are 
broadly in use. The most straight forward xenograft models are based on systemic 
cell  injection giving rise  to  disseminated tumors.  For  such models,  location of  the 
tumor is dependent on the injection site and influenced by the cancer cell type 
(Nguyen, Bos & Massague 2009). For example, after intracardial cell injection most 
tumors  are  found  in  several  sites  including  bone  marrow,  but  for  prostate  and  
breast cancers there is marked tropism to bone. In this type of model, the metastasis 
process avoids its early stages which leads to different profiles of tumors derived 
from experimental metastases and those from spontaneous metastases (Khanna, 
Hunter 2005). 
Subcutaneous tumors have very limited progression and very rarely induce 
metastases. However, some authors have reported metastatic spread of human 
cancer  cells  in  lymph  nodes  and  /  or  lungs,  detected  by  imaging  methods  
(Yamamoto et al. 2003, Hansen, Khanna 2004; Koike et al. 2009). These models are 
easy to develop and offer good reproducibility but they face the problem of being 
far from reality since the primary tumor grows in a complete different location and 
environment  than  in  a,  for  example,  real  colorectal  cancer  which  makes  their  
morphology differ very markedly from tumor biopsies, especially in the amount of 
stromal elements. All in all, the metastatic process develops in a completely 
different scenario and as a consequence, these cells released from the tumor very 
rarely turn into a mature tumor tissue. Notably, metastatic cells are not metastases; 
specific conditions are needed for metastatic cells to develop to a mature tumor 
tissue. Only a few amount of cells (1:100) released to blood flow successfully 
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develop into metastatic tumor tissue (Bouvet et al. 2006, Fukumura, Jain 2007; 
Nakagawa et al. 2004). Even when metastatic cells have reached a target organ, they 
can remain as single cells or micro-metastases until certain conditions permit their 
development to metastases (Bockhorn, Jain & Munn 2007). 
In humans, the liver is the most common receptor organ for metastases originating 
from colorectal tumors (Joyce, Pollard 2009). Therefore, three types of mechanisms 
have been used for human cell engraftment in murine liver: 1) direct implantation 
in liver parenchyma (Kollmar et al. 2006, Chiappa et al. 2009), 2) injection to the 
portal vein (Ni et al. 2006, Li et al. 2004) and 3) implantation of a primary tumor that 
releases metastatic cells through the portal system (Hiraoka et al. 2006, Ishizu et al. 
2007, Lee et al. 2006, Bouvet et al. 2006).  The first and second type  avoid selection 
of cells with metastatic potential,  so the hepatic tumors have similar phenotype to 
that of a primary tumor. This would partially explain the variability in the number 
of mice that develop intrahepatic tumors after cell administration (Chiappa et al. 
2009, Thalheimer et al. 2009). Interestingly, when cells are implanted in a location 
with vascular access to the liver through the portal system, like the cecum wall or 
spleen, tumorigenicity in the liver is more uniform than when cells are injected in 
the portal vein (Bouvet et al. 2006).  
 
1.6.3. Genetically engineered models (GEM) 
Mice can be genetically engineered to express molecular targets of interest or to 
express a foreign reporter protein with the aim of monitoring tumor induction and 
propagation in  the host.  Nowadays,  transgenic  mice  can develop cancers  in  many 
different organs with their own controlled progression closely resembling human 
carcinogenesis. Nonetheless, use of such models has been limited in 
translationalresearch because of their high cost, limited availability and other 
logistic and practical problems (de Jong, Maina 2010). 
The most common ways to produce GEM are the activation of oncogenes, the 
inactivation of tumor suppression genes or both. This is mostly done with the use of 
knock-out  models  (i.e.  a  certain  allele  is  suppressed  in  the  mouse  by  genetic  
manipulation of the germ line by deletion or mutation of a certain gene) and knock-
in models (i.e. an allele is added to the genome). The presence or lack of the gene 
can be restricted to a certain tissue or to a certain time, such models are defined as 
conditional knock-in/out models (Cheon, Orsulic 2011).  
The  study  of  human  colorectal  cancer  carcinogenesis  has  described  a  multi-step  
chain of  mutations which involve genes  in  the WTN (APC),  RAS,  TP53,  DCC and 
TGF? signaling pathways and trigger transformation to cancer cells (Vogelstein, 
Kinzler 2004). These mutations have been utilized in mice to develop GEM of 
- 44 - 
 
colorectal cancer. The first of such models to be established was the Apcmin/+ mouse, 
where the adenoma polyposis coli (Apc) gene was mutated through random 
chemical carcinogenesis (Moser, Pitot & Dove 1990). Although this model has been 
widely utilized in research, it presents several limitations. For example, while mice 
develop clearly adenomas, they do rarely produce adenocarcinoma, which are very 
frequent in human patients, and consequently do not invade other tissues. The 
location of the tumors in Apcmin/+ does not exactly correspond with clinical situations 
since most of them are located in the small intestines rather than in the colon. Still, 
despite these limitations, the Apcmin/+ model has been the most widely used GEM for 
cancer prevention studies that involve the gastro-intestinal tract (Green, Hudson 
2005). 
 
1.7. TUMOR MICROENVIRONMENT AS A BARRIER FOR ADENOVIRAL VECTORS 
DELIVERY 
Although different types of tumors feature their own particularities, certain 
characteristics,  not  found  in  normal  tissues,  are  common  in  several  or  all  tumor  
types (L Addison 2006, Kuppen et al. 2001). Due to particular morphological 
characteristics,  the  access  of  drugs  to  all  areas  of  the  tumor  is  normally  
compromised. Oncolytic adenovirus drugs are not an exception: poor spreading 
throughout the tumor mass and the difficulty to reach other cells by viral particles 
produced in situ are strongly linked to poor efficacy of the treatment (Sauthoff et al. 
2003). In normal tissues, interstitial pressure is slightly lower than intracapillary 
pressure, thus creating a transcapillary gradient between these compartments 
(Heldin et al. 2004). This outward transcapillary flow permits tissue homeostasis 
(i.e. tissue nutrition and oxygenation) and also facilitates drug availability. In 
contrast,  hydrostatic  and  osmotic  pressures  are  often  elevated  in  solid  tumors,  
which result in increased interstitial fluid pressure, creating a barrier for drug 
delivery (Heldin et al. 2004, Jain 1987a, Jain 1987b). In the case of virotherapeutic 
drugs, the acidic and hypoxic tumor environment, that rises rapidly as the distance 
with the nearest blood vessel increases, are limiting factors for adenovirus 
replication (figure 11). This is particularly true for colorectal carcinoma (Less et al.  
1992). The reasons for increased interstitial fluid pressure are not fully understood 
but are thought to involve an increased blood vessel permeability and leakiness due 
to tumor associated growth factors, lymph vessel abnormalities, interstitial fibrosis, 
abnormal contraction of the interstitial space by stromal fibroblasts and 
overexpression of tumor-related extracellular matrix (ECM) components (Heldin et 
al.  2004).  ECM,  as  a  physical  barrier,  may  also  directly  limit  the  spreading  of  the  
therapeutics (Beyer et al. 2011).  
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Figure 11: Particularities of tumor 
microenvironment that impede access and 
replication of adenoviral particles  
Oxygen partial pressure (pO2) and pH decrease 
dramatically as the distance to a blood vessel 
increases, thus creating hypoxic and acidic 
environment in the tumor that prevents 
adenovirus replication.  
Adapted from Trédan et al., 2007 
 
 
 
1.7.1. Use of proteases to increase viral spreading 
In  order  to  confront  the  problems  derived  from  the  poor  distribution  of  drugs  in  
general, and more precisely of adenovirus, ECM-degrading proteases can be 
administered with the treatment. In fact, some proteases have been given in order 
to enhance tumor spreading of chemical (Frost 2007) and biological (Eikenes et al. 
2004) drugs. Opposite to chemical drugs, that are not susceptible to degradation by 
proteases, viral vectors could get damaged by the action of proteases. Particularly, 
alterations in the proteic capsid can disturb viral infection of cells by degrading 
proteins needed for cell receptor binding (Kim et al. 2006). In any case, proteases 
have  been  shown  to  increase  viral  spread  of  oncolytic  adenovirus  and,  therefore,  
improve the antitumor effect of the virus therapy (Kim et al. 2006, Ganesh et al. 
2007, Ganesh et al. 2008). However, the presence of high levels of proteases in 
tumors is an indicator of poor prognosis (Ruppert et al. 1997, Nastase et al. 2011) 
and their influence on tumor invasiveness and metastases rises many concerns. In 
fact, some proteases have been explicitly reported to increase invasiveness in 
experimental models (Silvertown, Geddes & Summerlee 2003). For that reason, 
treatments for solid tumors involving proteases or protease activators are regarded 
as potentially risky. Therefore, the tendency of the treated tumor to metastases 
should be assessed when studying new therapeutic options. In the case of new 
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drugs or coadjuvant candidates, the relative gain in treatment efficacy should be 
evaluated together with the impact on metastases development. 
As a matter of fact, some treatments with adenovirus co-expressing proteases have 
shown to improve their  efficacy and avoid negative effects  on tumor progression.  
This has been shown in studies with non-replicating and replicating adenoviruses 
coding for relaxin, where mice treated with these vectors developed less metastases 
than untreated animals (Ganesh et al. 2007, Kim et al. 2006). Similarly, the 
metastatic potential of xenograft tumors in murine models did not increase after 
intravenous administration of hyaluronidase combined or not with the oncolytic 
adenovirus compared to non-treated animals (Ganesh et al. 2008). 
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2. AIMS OF THE THESIS 
? To utilize new capsid modified adenoviral vectors with reduced liver 
tropism and increased efficacy to transductionally target cancer cells in vivo. 
? To set up a new xenogeneic murine model of human metastatic colorectal 
cancer  which  can  be  followed-up  by  MRI  in  order  to  measure  primary  
tumor volume and development of liver metastases during and after 
treatment 
? To evaluate the use of proteases as coadjuvants of oncolytic adenovirus to 
increase their intratumoral spreading and, consequently, enhance 
antitumor activity. 
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?  
 
3. MATERIALS AND METHODS 
3.1. Cell lines 
Cell lines used in this Doctoral Thesis are summarized in Table 3. All cell lines were 
propagated in the conditions recommended by the manufacturer. 
 
Table 3: Summary of the cell lines used in the studies 
Cell line Origin Provider Used in 
HEK-293 (293) Human transformed embryonic kidney ATCC I, II 
293-6his Human transformed embryonic kidney Joanne T. Douglas* II 
211B Human transformed embryonic kidney Dan J. Von Seggern** II 
A549 Human lung adenocarcinoma ATCC I, II 
HCT116 Human colorectal carcinoma ATCC I, II, III, IV 
HT29 Human colorectal adenocarcinoma ATCC I, II, III, IV 
Co115 Human colon carcinoma ATCC I, II, IV 
SW480 Human colorectal adenocarcinoma ATCC I, II 
SW620 Human colorectal adenocarcinoma ATCC I, II, IV 
CaCo-2 Human colorectal adenocarcinoma ATCC I, II 
* Joanne T. Douglas (Department of Pathology, Division of Human Gene Therapy, University of  
Alabama at Birmingham, USA) 
*** Dan J. Von Seggern (Department of Immunology, IMM19, The Scripps Research Institute, La 
Jolla, CA, USA) 
 
 
3.2. Adenovirus 
A description of  all  the  adenoviruses  used in  the studies  is  to  be  found in table  4  
(replication uncompetent) and 5 (replication competent). Replication deficient 
viruses  are  deleted  for  E1A  and  have  both  luciferase  (Luc)  and  green  fluorescent  
protein (GFP) marker genes. 
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Table 4: Non-replicating viruses used in the study (all viruses are deleted for E1A and have both marker 
genes). 
Adenovirus Modification / s Used in Reference 
AdTL Wild type 5 capsid. I, II  
DATL 
Y477A substitution in DE loop of fiber knob for CAR ablation. 
Penton base’s RGD domain mutated to RGE for ?v? integrin 
ablation. 
6xhistidine carboxy-terminal tag for the propagation in 293-
6his cells 
I, II 
(Nettelbeck et al. 
2004) 
AdTLG Fiber shaft’s KKTK domain mutated to GATK for HSPG 
ablation. 
I, II 
(Bayo-Puxan et al. 
2006) 
AdTLGR 
RGD insertion to HI loop of fiber knob for ?v? integrin 
targeting. 
Fiber shaft’s KKTK domain mutated to GATK for HSPG 
ablation. 
I, II 
(Bayo-Puxan et al. 
2006) 
AdTLYG 
Y477A substitution in DE loop of fiber knob for CAR ablation. 
Fiber shaft’s KKTK domain mutated to GATK for HSPG 
ablation. 
I, II 
(Alemany, Curiel 
2001; Bayo-Puxan 
et al. 2006) 
AdTLYGR 
Y477A substitution in DE loop of fiber knob for CAR ablation. 
RGD insertion to HI loop of fiber knob for ?v? integrin 
targeting. 
Fiber shaft’s KKTK domain mutated to GATK for HSPG 
ablation. 
I, II 
(Alemany, Curiel 
2001; Bayo-Puxan 
et al. 2006) 
AdTLY Y477A substitution in DE loop of fiber knob for CAR ablation. II 
(Alemany, Curiel 
2001) 
Ad5luc1RGD RGD insertion to HI loop of fiber knob for ?v? integrin 
targeting. 
II, III (Wu et al. 2002b) 
AdTLRGDK 
Fiber shaft’s KKTK domain mutated to RGDK for ??? integrin 
targeting. 
HSPG ablation via mutated KKTK. 
I, II I 
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Propagation of AdTLG, AdTLYG, AdTLGR and AdTLYGR performed done in 211B 
cells for 3 rounds followed by a last round of amplification in 293 cells as described 
previously(Bayo-Puxan et al. 2006). DATL was propagated in 293-6his as reported 
before elsewhere (Bayo-Puxan et al. 2006). The other non-replicating viruses were 
propagated in 293 cells, while replication competent viruses were amplified in A549 
cells. All viruses were purified on cesium chloride gradients. The particle 
concentration  was  measured  at  260  nanometers  (nm)  by  spectrometry  and  by  a  
standard  50%  tissue  culture  infective  dose  (TCID50) test to determine functional 
units.  In  a  nutshell,  this  test  estimates  the  dose  of  virus  required  to  produce  
cytopathic effect in 50% of inoculated cell culture samples. The test is performed by 
infecting 293 cells with a series of dilutions of the virus stock with unknown 
concentration. After 10 days, the relative number of wells with cells presenting 
cytopathic  effect  is  counted  and  results  are  given  in  TCID50 units. The rationale 
behind the conversion of TCID50 units into plaque forming units (pfu) is that 1 ml of 
viral stock is expected to produce double the amount of plaques on cell monolayers 
than  of  TCID50 units,  provided  the  test  was  done   under  similar  conditions.  A  
precise estimate of the pfu/ml titer is obtained mathematically from the results of 
the TCID50 test,  in  TCID50 units,  using  the  Poisson  distribution  (Reed,  L.J.,  &  
Muench, H. 1938). 
 
Table 5.   Replication competent viruses used in the study. 
Adenovirus Modification / s Used in Reference 
WT Replicating wild type 5 virus. II  
WT-RGD 
RGD insertion in HI loop of fiber knob for ?v? integrin 
targeting. 
II 
(Cascallo et al. 
2007) 
WT-RGDK 
Fiber shaft’s KKTK domain mutated to RGDK for ?v? integrin 
targeting. 
HSPG ablation via mutated KKTK 
II I 
Ad5-?24-RGD 
24-bp deletion in the CR2 region of E1A. 
RGD insertion in HI loop of fiber knob for ?v? integrin 
targeting. 
III, IV 
(Dmitriev et al. 
1998, 
Bauerschmitz et 
al. 2002) 
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3.3. Animals 
All animal experiments were conducted according to the rules set by the Federation 
of European Laboratory Animal Science Associations and the Provincial 
Government of Southern Finland. Pathogen-free, 3-4-week-old female NMRI nude 
mice were purchased from Taconic (Ejby, Denmark), Charles River (Sulzfeld, 
Germany) and Scanbur (Sollentuna, Sweden), while 10-11-week-old female SCID 
(severe combined immunodeficiency) mice were obtained from Taconic, Charles 
River, and Harlan (Horst, Holland). Animals were quarantined for 2 weeks. They 
were fed ad libitum and maintained in a HEPA-filtered environment with cages, 
food, and bedding sterilized by autoclaving. 
 
3.4. In vitro studies 
3.4.1. Adenovirus transduction assay (I, II, IV) 
One day before infection, cells were seeded in 24 or 96-well plates. Viruses in 
growth medium were added at the desired dose of viral particles (VP) per cell and 
incubated for 20 hours for 293 cells and for 48 hours for the other cell types. In IV, 
some of the samples were incubated at the same time with isomolar doses of 
different proteases. 30 minutes after the growth medium was renewed. To quantify 
luciferase activity and protein content, luciferase assay reagent (Luciferase Assay 
System, Promega, Madison, WI, USA) was used and measured in a luminometer 
(Berthold Junior; Berthold). Protein concentration of supernatant was quantified 
using Bio-Rad protein assay. Results are expressed in relative light units (RLU) per 
?g of protein. 
 
3.4.2. Oncolytic potency in human colorectal cancer cells (I, II, IV) 
Cells were infected with replication competent viruses or a non-replicating control 
virus  and,  after  1  or  2  hours,  infection  medium  was  replaced  with  another  
containing  5%  FCS.  In  the  experiments  reported  in  IV,  growth  medium  was  
replaced again after 12 hours and equimolar doses of different proteases were 
added in medium with 5  % FCS.  Growth medium was renewed every other  day.  
Eight to 11 days later (at the optimal time point for each cell line), cell viability was 
analyzed with the mitochondrial activity-based 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxy-methoxyphenyl) -2-(4-sulfophenyl)-2H- tetrazolium (MTS) assay (Cell Titer 
96 AQueous One Solution Cell Proliferation Assay; Promega, Stockholm, Sweden). 
All statistical analyses were carried out with SPSS 15.0 for Windows. One-way 
analysis of variance (ANOVA) followed by Dunnett´s Pairwise Multiple 
Comparison t-test was applied. 
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3.5. Mouse models  
3.5.1. Subcutaneous tumor xenograft models (I, IV) 
Subcutaneous tumors were implanted in both flanks of NMRI nude mice by 
injection  of  the  corresponding  human  cancer  cells  in  a  given  volume  of  DMEM  
without supplements.  
 
3.5.2. Intra-hepatic tumor model of colorectal cancer (II) 
The surgical procedure was similar to what has been previously described (Yu et al. 
2004). Mice were anesthetized with ketamine (Ketaminol® 75 mg/kg; Intervet, 
Boxmeer, Netherlands) / dexmedetomidine (Dexdormitor® 1 mg/kg; Orion Pharm, 
Espoo, Finland) mixture and the spleen was exteriorized through a left lateral flank 
incision. Tumors were established by intrasplenic injection of 2 x 106 HCT116 cells 
suspended  in  50  µl  of  serum-free  growth  media  using  a  27-gauge  needle.  The  
injection site of the spleen was pressed with a cotton stick wet in iodine-polividone 
solution (Betadine®;  Leiras, Helsinki, Finland) in order to remove extravasated cells 
and ensure hemostasis. The peritoneum and skin were closed in a single layer using 
surgical thread. Finally, atipamezole (Antisedan® 1  mg/kg;  Orion  Pharm,  Espoo,  
Finland) was injected subcutaneously to reverse anesthesia. 
 
3.5.3. Metastatic human colorectal cancer model (III, IV) 
Tumors were established by intrasplenic injection of 1x106 HT29 cells as described in 
the section 3.5.2.  
 
3.6. In vivo studies 
3.6.1. Biodistribution in a tumor xenograft model of mice (II) 
The mouse model described in 3.5.2 was used. Tumors were left to grow and 21 days 
after intrasplenic injection of HCT116 cells, 3 x 1010 VP  of  AdTL,  AdTLGR,  or  
AdTLRGDK in 150 µl of PBS were injected through the tail vein of NMRI nude mice. 
After  48  hours,  mice  (n=  5  in  each  group)  were  sacrificed  and  organs  and  tumors  
were harvested for luciferase analysis. Data was normalized for protein 
concentration by Pierce BCA Protein Assay Kit® (Thermo  Scientific,  Rockford,  IL,  
USA). 
 
3.6.2. Antitumor efficacy in a intra-hepatic tumor model of colorectal cancer (II) 
Tumors were implanted as described in 3.5.2. On day 23 and 24 after cell injection, 
mice were treated with two intravenous injections of 3 x 1010 VP of WT, WT-RGD, or 
WT-RGDK  in  100  µl  volume  of  PBS  (n=  4,  11,  and  9,  respectively).  Mock  animals  
(n=9) were treated with PBS only. Tumor volume was followed up in the abdomen 
by MRI. Mice were imaged under isoflurane (Baxter, Helsinki, Finland) anesthesia. 
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30  minutes  before  imaging,  1  mg/kg of  contrast  agent  Endorem® (Guerbet, Roissy 
CdG Cedex, France) in 100 µl volume was administered intravenously.  
Tumor  tissue  areas  in  the  liver  were  measured  in  every  slice  and  a  total  tumor  
volume was calculated using the formula:  ? (Area*slice  height)  or  ? (Area*0.7).  In  
order to distinguish hepatic tumor tissue from vessels or other structures present in 
the liver, all images were compared to a baseline image of each mouse taken before 
tumor implantation. Daily volumes of hepatic tumor tissue were normalized to 
tumor volume a day before treatment. Animals were examined daily for behavioral 
or physical signs of pain or distress and survival data was collected.  
 
3.6.3. Viral replication of adenovirus in intra-hepatic colorectal cancer tumors 
in mice (II) 
The xenograft  model described in 3.5.2. was used: mice were treated 29 days after 
cell injection with 3 x 1010 VP of WT, WT-RGD, or WT-RGDK in 100 µl of PBS, or PBS 
alone (mock) (5 in all groups, except for WT-RGDK 6). Three days after treatment, 
mice were sacrificed and hepatic tumors were harvested, homogenized and diluted 
in growth media. After three freeze and thaw cycles (-80C / room temperature), 
tumor lysates were centrifuged, supernatant was collected and added to 293 cells to 
perform TCID50 test. Plaque forming units per ml (pfu/ml) values were normalized 
for total hepatic tumor volume and the final values were given as amount of 
pfu/tumor. 
 
3.6.4. Effect of proteases on the oncolytic potency of an adenovirus in a 
subcutaneous murine model of colorectal cancer (III, IV) 
The subcutaneous murine model described in 3.5.2.  was used. Tumors were allowed 
to grow for 14 days. Thereafter, 10-9 mols of each protease in an injection volume of 
25 ?l  of  PBS  were  injected  intratumorally.  Control  animals  received  PBS  only.  The  
number  of  animals  in  each  group  was  4.  Half  of  the  animals  from  each  protease  
group received 1.0 x 107 pfu of Ad5-?24-RGD intratumorally 24 hours later in a 50 ?l 
volume of  DMEM without FCS or antibiotics. Tumor volumes were calculated 
according to  the formula V = ½ *  length *  width ^ 2 (Euhus et al. 1986; Tomayko, 
Reynolds 1989) at day 5 and data was expressed as relative volumes normalized to 
tumor volume a day before adenoviral treatment.  
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3.6.5. Oncolytic adenovirus efficacy and influence on tumor progression in a 
metastatic murine model of colorectal cancer (III, IV) 
The mouse model described in 3.5.3.  was used for these tests. Ad5-?24-RGD and/or 
MME were administered 21 days after tumor cell implantation by intratumoral 
injection to splenic primary tumors. Solution containing 2.3 x 10-10 mols of MME in 2 
?l PBS and adenoviral suspension containing 1.1 x 107 VP in 8 ?l PBS were prepared 
extemporally and a single microinjection of 10 ?l volume was given to each animal. 
Mock animals received PBS only. Tumor growth (both in the spleen and liver) was 
followed weekly with MRI for 4 weeks. Tumor volumes were estimated using the 
formula  V  =? (Area  x  slice  thickness).  For  intrahepatic  tumors,  the  total  area  
occupied by tumors in each slice was included in the formula. The number of 
animals in each group was 12 (mock), 10 (Ad5-?24-RGD), 8 (MME), and 12 (Ad5-
?24-RGD + MME). 
 
3.7. Magnetic resonance imaging 
MRI studies were performed with a 4.7 T scanner (PharmaScan, Bruker BioSpin, 
Ettlingen, Germany) using a 90-mm shielded gradient capable of producing a 
maximum  gradient  amplitude  of  300  mT  /  m  with  an  80-?s  rise  time.  A  linear  
birdcage  RF  coil  with  an  inner  diameter  of  38  mm  was  used.  T2-weighted  images  
were acquired using rapid acquisition with relaxation enhancement (RARE) 
sequence (TR / TEeff = 3767/ 36 ms, matrix size = 256 x 256, Rare Factor = 8, field-
of-view = 33 x 33 mm2, 32 slices, slice thickness = 0.7 mm, number of averages = 8). 
 
3.8. Statistics 
All statistical analyses were done with SPSS 15.0 or PASW Statistics 17 for Windows. 
One-way analysis of variance (ANOVA) followed by Dunnett´s Pairwise Multiple 
Comparison t-test was used to analyze the differences in the cell killing potency of 
viruses in vitro (studies II, III and IV) and tumor growth and virus replication in vivo. 
The Mann-Whitney test was used to analyze the differences in the biodistribution 
and tumor-to-organ ratios. Survival data was plotted into a Kaplan–Meier curve and 
groups were compared pair-wise with a log-rank test. A value for p < 0.05 was 
considered statistically significant.  
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4. RESULTS AND DISCUSSION 
4.1. RGD insertion into fiber enhances Ad5 in vitro transduction to cancer cell 
lines (II) 
Many capsid modifications have already proven to be effective as tools for ablating 
in vitro viral transfection to liver cells, either by impeding binding to CAR, HSPG or 
?v?-integrins.  Unfortunately, those receptors also play a role in the viral entry 
mechanism to cancer cells. In order to establish which fiber modifications aimed to 
decrease liver tropism, still permit sufficient tumor targeting, a panel of several 
human cancer cell lines were transduced with non-replicating luciferase-expressing 
adenoviral vectors.  
Tyrosine-to-alanine substitution (Y447A) in the DE-loop of the fiber knob hinders 
binding to CAR (AdTLY). This modification is enough to eliminate gene delivery to 
cancer cells, thus confirming the crucial role of CAR for in vitro infection of cancer 
cells. Obviously, no better results were obtained with DATL, a vector which adds to 
AdTLY  the  mutation  of  the  integrin  binding  sequence  RGD  to  RGE.  Similarly,  
vectors  modified  to  interfere  with  HSPG  binding  (AdTLG)  showed  reduced  gene  
transfer  compared  to  Ad5.  As  expected,  double  ablations  for  CAR  and  HSPG  
(AdTLYG) binding reduced gene expression levels as well. On the contrary, vectors 
where a RGD tripeptide motif had been inserted into the HI loop of the fiber knob 
(Ad5TLRGD) or substituted for the fiber shaft KKT domain (AdTLRGDK) proved to 
be clearly superior to transduce cancer cells (up to 800-fold and up to 145-fold 
respectively). Differences between gene delivery of AdTLRGDK and AdTLRGD 
depended on the cell line studied. In general, AdTLRGD infected all cell lines more 
efficiently than the vector with the RGD insertion at the HI-loop when the shaft had 
also been mutated (AdTLGR). AdTLRGDK transduced SW480 and SW620 cells as 
well as AdTLRGD did, but AdTLRGDK transduced Co115 and CaCo-2 cells better 
than AdTLRGD. Nevertheless, in a shaft-mutated background, RGD generally 
mediated  better  transduction  when  located  at  the  KKTK  site  than  at  the  HI-loop  
(AdTLRGDK vs. AdTLGR). This indicates that the shaft mutation GATK impedes  
proper  exposure of  RGD into the HI-loop,  in  agreement  with other  authors  (Bayo-
Puxan et al. 2006), and points out the potential of the KKTK domain of the Ad5 shaft 
as an alternative locus to insert tumor-selective peptides.  
These  results  justify  the  use  of  RGD  insertions  either  in  knob  or  shaft  domain  to  
rescue vector infectivity to cancer cells after having been detargeted from 
CAR/HSPG-binding by other modifications in the capsid. Thereby, this first 
screening in several in vitro models represents a starting point to define the 
characteristics of vectors displaying additional RGD moieties in the fiber protein. 
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4.2. Biodistribution of adenoviral vectors with RGD insertions in the capsid (II) 
Removal of the KKTK putative domain, by mutation of KKTK to GATK, as a unique 
capsid  modification  has  proven  to  be  effective  to  reduce  liver  transduction  in vivo 
(Bayo-Puxan et al. 2006). Unfortunately, cell detargeting is not specific to normal 
cells and, as discussed in section 4.1, in vitro results showed that transduction levels 
with this vector in different cancer cells were lower compared to a similar virus with 
wild-type capsid. As those in vitro results  also  pointed  out,  insertions  of  the  ??? 
integrin-binding moiety RGD in KKTK-mutated vectors were effective to rescue 
their infectivity towards cancer cells. 
In  order  to  define  how  these  RGD  insertions  in  KKTK-mutated  vectors  influence  
their biodistribution in vivo, NMRI nude mice bearing intrasplenic and intrahepatic 
HCT116 tumors were systemically injected with 3 × 1010 VP of AdTL (Ad5 control), 
AdTLGR  (RGD  in  the  HI  loop;  KKTK  mutated  to  GATK),  or  AdTLRGDK  (KKTK  
mutated to RGDK). At 48 hours, luciferase activity and protein concentration of 
organs and tumors (in spleen and liver) were measured. 
The vector AdTLRGDK displayed the highest transgene expression in both types of 
tumors, but only in splenic tumors the result was statistically significant. 
Specifically, in comparison with unmodified virus, AdTLRGDK increased spleen 
and liver tumor transduction six- and five-fold while increase with AdTLGR was six 
and four-fold respectively. Both RGD-modified viruses showed increased hepatic 
tumor-to-liver and splenic tumor-to-spleen ratios in transgene expression. 
Interestingly, AdTLRGDK and AdTLGR viruses presented very different 
biodistribution profiles. In normal liver tissue, AdTLGR displayed 10-fold lower and 
AdTLRGDK 23-fold higher transgene expression if compared to AdTL. A similar 
trend was seen in the spleen, but the difference between AdTLRGDK and AdTL was 
not statistically significant. For the kidneys and lungs, the only statistically 
significant difference was enhanced gene transfer of AdTLGR in comparison with 
AdTL. In the heart, no significant differences in the efficacy of gene transfer was 
seen between viruses.  
All in all, AdTLRGDK showed an apparent tendency to present higher transduction 
rates than the other viruses in all organs. However, when the values were analyzed 
as tumor-to-liver ratios, relative targeting of tumors was improved but independent 
of the RGD insertion site. Ratios were compared to un-modified viruses. The results 
for these modified vectors show a more favorable profile in tumor targeting with a 
lower liver-to-tumor ratio than the wild-type.  
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4.3. Oncolytic potency of RGD-modified viruses in vitro (I, II) 
Capsid modifications studied the previous sections with non-replicating vectors 
were brought also to the context of replication competent (oncolytic) adenoviruses. 
WT-RGD and WT-RGDK were used. The first of them has the RGD moiety in the 
fiber  knob  while  the  second  presents  the  KKTK  ? RGDK  substitution  in  the  fiber  
shaft. Oncolytic potency of replication competent viruses and WT control virus was 
analyzed in six colorectal cancer cell lines by MTS assay. At the lowest viral dose (0.1 
VP/cell), RGD modified viruses killed cells more effectively in comparison with WT 
in three out of six cell lines. At higher viral doses, however, RGD insertion in the HI 
loop of the fiber (WT-RGD) or in the shaft (WT-RGDK) did not increase the oncolytic 
potency and all three replication competent viruses showed an equal cell killing 
capability in all six established colorectal cancer cell lines. The E1-deleted Ad5 
control virus did not cause oncolytic cell death.  
Even if at the low doses RGD insertion plays a meaningful role in oncolytic efficacy 
in some cell lines, this effect is overcome by the rapid cell killing seen at doses of 1 
VP/cell  or  higher.  This  effect  is  somehow  surprising  compared  with  the  results  
obtained from non-replicating viruses (section 4.1). Nonetheless, the fact that 
replication competent viruses exponentially accumulate in the culture medium, 
while luciferase expression of non-replicating vectors relies on the one-time dose 
transduction  of  the  target  cells,  might  explain  these  results.  In  any  case,  the  
possibility of a decreased cancer cell lysis potential of the KKTK-mutated virus WT-
RGDK is discarded with this experiment. However, for the reasons explained above, 
further research should clarify whether the influence of such modifications is 
undetected  in the context of this particular experimental method or if it is simply 
irrelevant when applied to oncolytic adenoviruses. 
 
4.4. Antitumor efficacy of RGD-modified viruses in metastatic model of human 
colorectal cancer (II) 
The  benefits  of  RGD  modified  vectors  in  oncolytic  adenovirus  therapies  were  
evaluated with the following study. Human colorectal cancer cells (HCT116) were 
injected  into  the  spleen  of  NMRI  nude  mice  and  intrasplenic  and  hepatic  tumors  
were allowed to grow for 23 days. Two intravenous injections of viruses were given 
on consecutive days, and hepatic tumor volumes were followed by MRI thereafter. 
By day 21,  tumors  in  all  treated groups were already three times bigger  than non-
treated tumors. However, no differences could be observed between capsid 
modified and unmodified vectors. Nevertheless, on day 35 (end of the experiment), 
only WT-RGD and WT-RGDK treated animals showed statistically significant 
reduction in tumor growth in comparison with non-treated animals, while lower 
differences were observed between WT and mock groups. Median survival of mice 
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treated with WT, WT-RGD and WT-RGDK was of 44.5, 41, and 46 days, respectively, 
while it dropped down to 28 days for untreated animals. In any case, the differences 
were statistically significant.  
It  is  interesting  to  see  how  the  strong  influence  of  capsid  modifications  in  non-
replicating  vectors  (see  section  4.1)  to  increase  cancer  cell  infectivity  does  not  
produce major effects when applied to replication competent vectors. One reason for 
that is that the effects on infectivity could be overcome by the potent replication rate 
of oncolytic viruses. In any case, if changes in liver targeting really influence toxicity 
of  the  treatment,  viruses  with  RGD  insertions  would  be  more  safe  and,  therefore,  
could be administered with higher doses, which would improve treatment efficacy. 
Modified particles did not impede a long persistence of the virus in target tissue as 
was seen after assessing the amount of actively replicating viruses in tumor lysates 
by TCID50. All treated tumors presented measurable titers for replicating virus, 
showing that modified capsids are capable of sustained active replication in a tumor 
target tissue. However, no statistically significant differences in the functional titers 
were observed between different viruses.  
 
4.5. Analysis of transgene expression and oncolytic potency of RGD-modified 
adenovirus vectors co-administered with proteases in vitro (IV) 
Broad spectrum proteases  can degrade many components  of  tumor ECM and ease  
oncolytic adenovirus distribution throughout the tissue. Therefore, we hypothesized 
that co-administration of proteases with oncolytic adenovirus therapies can improve 
viral spreading in order to maximize tumor volume reduction.  
As a first step to validate proteases as good coadjuvants for oncolytic administration, 
we aimed to study whether proteases have any effect on cancer cells that would alter 
transduction efficiency of adenovirus vectors. Thereby, human colorectal cancer cell 
lines HCT116 and HT29 were infected with Ad5lucRGD alone or in combination 
with equimolar doses of either elastase, hyaluronidase, relaxin, or MME. In general, 
proteases  had  no  major  effect  on  the  transduction  efficiency  of  Ad5lucRGD.  
However, for HCT116 cells, hyaluronidase produced a 2-fold decrease of transgene 
expression at the lowest viral dose. Relaxin also decreased transgene expression in 
less than 2-fold in combination with a viral dose of 1000 VP/cell, while MME 
increased transgene expression at viral doses of 200 and 1000 VP/cell (2 and 1-fold). 
In HT29 cells, all proteases slightly increased transgene expression. Relaxin and 
hyaluronidase in combination with lowest dose of the oncolytic virus gave the most 
relevant increase in transduction (6 and 9-fold). Importantly, no incompatibilities 
were detected between any of the proteases or the cells used for the study that 
would have an important decrease on viral infectivity.  
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The possible effect of proteases on the viability of human colorectal cancer cell lines 
and their capability to permit adenovirus replication was also tested. To this end, 
cancer cell monolayers were infected with 4500 VP/cell of the oncolytic virus Ad-
?24-RGD and incubated for 12 hours. This period of time was long enough to permit 
maximum adenovirus transduction but not complete replication. After this 12-hour 
period, growth media was renewed with media containing equimolar doses the 
proteases. Cell viability was assessed regularly by the MTS assay.  
First cells were treated with the proteases only. Of note, the MTS test detected some 
decrease in viability with cells incubated with MME. In contrast, hyaluronidase, 
relaxin, and elastase either slightly increased or had no effect on cell viability. The 
only exception for this was in the case of HT29 cells incubated with hyaluronidase, 
where  cell  viability  decreased  moderately  after  7  days  of  incubation.  The  effect  of  
proteases in combination with oncolytic adenovirus on cell viability was assessed 
similarly  and,  in  this  case,  none of  the proteases  showed any difference in  the cell  
killing in comparison to virus treatment alone.  
Although  this  assay  does  not  take  into  account  the  effect  of  ECM  on  intratumoral  
viral penetration, its reveals no major negative effect of proteases on the cells, like 
inhibition of viral replication. There is, however, no reason to reject any of the 
proteases for further studies. 
 
4.6. Construction and validation of a new murine model of metastatic colorectal 
cancer (III) 
A new animal model was designed to globally understand the effects of anticancer 
drugs in the context of a binary system, where both the treated primary tumor and 
metastatic tumors can be followed accurately during the lifespan of the animal. This 
new murine model features an intrasplenic primary tumor that spontaneously 
metastases to the liver through the portal system. There is at least one week of 
margin between the time the primary tumor is big enough to be intratumorally 
treated (i.e. presents a diameter of 2 mm or larger) and the detection of the first liver 
metastases, thus providing a good platform to test the influence of experimental 
treatments on tumor progression and metastases.  
The  injection  of  a  certain  volume  of  liquid  and  subsequent  development  of  a  fast-
growing tissue, like a xenograft tumor tissue, requires a recipient organ that is solid 
and  resistant  enough  to  sustain  it.  We  previously  saw  that  mature  NMRI-NUDE  
mice spleens gathered the necessary characteristics to do so. Unfortunately, given 
that mice have to remain under isoflurane anesthesia for 10 minutes or more during 
MRI, hairless NMRI-NUDE mice rarely survived the process. This is why SCID mice 
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were used as no death related to hypothermia was ever seen thanks to their thick fur 
layer and all the mice imaged survived the session. As a drawback, mutations used 
to generate deficiencies of the immune system in SCID mice delay normal spleen 
development (Seymour, Sundberg & Hogenesch 2006) and lead to morphologically 
immature spleens in adult mice. Those spleens were more small, soft, and pale than 
in wild type (NMRI) mice and too fragile to even sustain a small volume injection. In 
fact,  these properties were so striking that they could even be observed with MRI, 
where the spleens of SCID mice appear squeezed between neighboring organs due 
to their malleable consistency. Interestingly, important differences in spleen 
morphology were seen not only between mice strains, but also among mice from a 
different provider. Therefore, the animals had to be of at least 125 days of age for the 
splenic tumors to be implanted. At that time, all mice obtained from Taconic 
presented mature spleens at the time of imaging, so they were selected for further 
tests. 
A crucial prerequisite for our model is that a clear distribution in time exists between 
the formation of the primary tumor and the subsequent spreading and detection of 
liver metastases. It has been shown that injection of many cancer cells in the spleen 
leads  to  hepatic  tumors  caused  by  direct  implantation  and  not  by  a  metastatic  
process in the host organism (Bouvet et al. 2006). In order to avoid this, we followed 
splenic and hepatic tumor growth after intrasplenic injection of different human 
colorectal cancer cell lines: Co115, HCT116, SW620, HT29. While  Co115 cells 
produced intrasplenic and intrahepatic tumors between 14 and 43 days after cell 
injection in 5/8 and 3/8 animals respectively,  HCT116 cells, produced intrasplenic 
tumors after 7 days in 5/7 and after 32 days in 6/7 animals. SW620 did not induce 
tumors  neither  in  the  spleen  nor  liver  in  any  of  the  animals  (0/4).  For  HT29,  all  
animals (8/8) developed both primary tumors and metastases. In all cases, 
intrasplenic tumor growth was detectable by 21 days after cell injection while 
tumors in the liver were first observed 1 to 4 weeks later, starting from day 28 after 
cell implantation. According to these data, HT29 was the cell line that showed less 
intra-individual variability. Indeed, the portal system allows easy spread of 
metastatic  cells  from  splenic  tumors  to  the  liver  but  may  also  mediate  direct  
implantation of the cells in hepatic tissue after intrasplenic injection. Therefore, it is 
crucial to distinguish between these events. Direct implantation is something we 
observed with HCT116, where 2/7 mice presented hepatic tumors but no 
intrasplenic  ones  and  1  mouse  presented  a  hepatic  tumor  several  days  before  the  
splenic tumor grew. In opposition to this, with HT29, all mice developed liver 
tumors 7 to 21 days after the appearance of primary intrasplenic tumors, strongly 
supporting the metastatic origin of these tumors. This delay in intrahepatic tumor 
development  and  the  fact  that  in  all  mice  it  occurs  at  least  one  week  after  splenic  
tumor detection, demonstrates a metastatic origin for the liver tumors. 
- 61 - 
 
For its optimal utility, the imaging method should allow fast and real time 
identification of tumor development in the spleen and the liver. A general difficulty 
with MRI is to differ between tumors and stromal elements such as vessels, the gall 
bladder, hepatic lymph nodes or ligaments. Therefore it was important to compare 
our MRI results with laparotomy findings. Some mice were thus inspected through 
laparotomy to compare the location, size and shape of the tumors to their MRI 
images. Also, the entire organ and a section of the organ, where the tumor was 
engrafted,  gave  an  accurate  idea  of  the  location  and  shape  of  the  tumor,  which  
corresponded  to  its  predicted  location  and  shape  by  MRI.  This  demonstrates  that  
MRI is a reliable method for splenic and liver tumors diagnosis in mice.  
 
4.7. Use of the optimized mouse model to study the effects of an experimental 
treatment (IV) 
Animals were implanted with HT29 cells and imaged with MRI weekly for 6 weeks. 
Following previous model validation results, mice developed both intrasplenic 
(primary) tumors and liver metastases which were detected in each case 1 to 3 weeks 
after intrasplenic tumor formation. At least one week before metastases detection, 
primary tumors were considered suitable for a 8 µl microinjection of the therapeutic 
agent. Of note, this time window of at least one week makes the model useful for the 
evaluation of possible pro- and anti-metastatic properties of the treatment. 
Murine  cancer  models  for  drug  design  should  be  sensitive  enough  to  antitumor  
drugs’  effects  and,  thus,  produce  a  clear  differential  response.  In  the  case  of  this  
murine model, changes on splenic and metastatic tumor growth and number of 
metastases should be both easily detectable to permit good quality of the data 
collected. Oncolytic adenoviruses have been widely tested in mouse xenograft 
models of human cancers and shown to effectively reduce tumor masses (Liu 2006). 
Therefore, oncolytic virus Ad5-?24-RGD was used as an example of an antitumor 
agent to assess model responsiveness. When a moderate dose of this drug was used 
as a single intratumoral  administration , significant intrasplenic tumor growth 
reduction, detected after a latency period of two weeks (i.e. days 21 to 35 after tumor 
implantation) was seen. This response was clearly different to untreated mice, whose 
tumors grew steadily until the end of the experiment. Follow up of liver metastases 
did not reveal any pro-metastatic effect linked to the oncolytic virus administration. 
On  the  contrary,  a  reduced  number  of  metastatic  lesions  as  well  as  significantly  a  
smaller amount of total tumor mass in the liver were observed. 
In conclusion, this murine model is capable of clear, accurate and sensitive detection 
of changes in tumor volume. It also permits repeated and frequent measurements 
without the need of sacrificing the animal, thus reducing importantly the amount of 
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mice required for the experiment. Last but not least, it detects the possible effects of 
the administered drug or intervention on the amount and growth rate of metastases 
originated from the primary tumor. 
 
4.8. Effect of protease pre-treatment on adenoviral oncolytic potency in 
subcutaneous tumors (IV) 
Given the lack of incompatibilities seen with relaxin, hyaluronidase, elastase or 
MME in conjunction with oncolytic adenovirus to treat solid tumors, all four 
proteases were included in an in vivo screening to test the effects of the protease on 
the efficacy of cancer treatment. Subcutaneous tumors were implanted by HCT116 
cell  injection  in  NMRI  nude  mice  (four  mice  per  group;  two  tumors  per  animal).  
Mice were treated intratumorally with one of the proteases and, 24 hours later, half 
of the animals were infected with the oncolytic adenovirus Ad5-?24-RGD. Control 
animals  (four  animals  per  group)  received  PBS  intratumorally  on  two  consecutive  
days,  or  PBS  followed  by  intratumoral  injection  of   the  oncolytic  virus.  Tumor  
volumes were measured after 5 days and normalized to their volume one day before 
treatment with oncolytic adenovirus.  
The dose used of the oncolytic virus treatment alone did not reduce tumor growth 
significantly. On the contrary, a pronounced inhibition was seen with the 
combination treatment of oncolytic virus and each protease, showing how some of 
the proteases (i.e. relaxin, elastase and MME) improved significantly the efficacy of 
the treatment.  No statistically significant difference between oncolytic virus therapy 
and combination therapies was detected. None of these proteases reduced tumor 
growth significantly alone, except hyaluronidase. However, important reductions 
(over 2-fold) were observed between untreated tumors and those treated with MME. 
This could be related to some effect of the protease on the tumor microenvironment, 
for  example  on  the  vascularization  of  the  tissue  and  hence  the  amount  of  liquid  
retained. Also some effect of MME on the tumor cells could be expected, considering 
that MME, decreased cell viability in vitro, as described in section 4.5. Animals did 
not show signs of post-treatment distress in any treatment groups. 
 
4.9. Effect of MME on oncolytic efficacy of adenovirus in splenic primary tumors 
and liver metastases (IV) 
The  protease  MME  was  selected  among  other  proteases  for  its  inhibitory  effect  on  
tumor growth seen in vitro and for  its  positive  effects  on tumor microenvironment  
described in the scientific literature (Acuff et al. 2006, Cornelius et al. 1998, Dong et 
al. 1997, Gorrin-Rivas et al. 2001, Houghton et al. 2006, Kerkela et al. 2001, Shi et al. 
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2006, Yang et al. 2001). Human cancer cell line HT29 was used to establish 
intrasplenic tumors in SCID mice. 21 days after tumor implantation, all intrasplenic 
tumors  sizes  were  at  least  of  2  mm  in  diameter  and  the  liver  did  not  present  any  
metastases. Animals (8 to 12 animals per group) were injected intratumorally with 
Ad5-?24-RGD,  MME,  or  combination  of  both.  Tumor  volumes  in  the  spleen  and  
liver,  and  the  number  of  liver  metastases  were  followed  weekly  with  MRI.  
Importantly, metastases appeared at least one week after treatment injection, being 
their development directly influenced by the treatment. 
Untreated and MME-treated splenic tumors grew steadily until the end of the 
experiment. However, MME-treated tumors grew slightly more slow, possibly due 
to the effects of MME on tumor cells or tumor microenvironment suggested in 
section  4.8.  Equal  reduction  in  tumors  treated  with  oncolytic  adenovirus  or  in  
combination with MME was observed. Both treatments showed statistically 
significant difference in comparison to untreated tumors at three weeks after 
treatments and thereafter. No differences were observed between oncolytic 
adenovirus with or without MME, unlike it happened in the subcutaneous model. In 
order to improve the effect of MME as coadjuvant, it could be useful to increase its 
dose, since no toxic effects were seen with the doses of protease used for the present 
study. 
In general, liver tumors could be first detected by MRI four weeks after injection of 
cancer cells to the spleen. All mock treated (PBS) animals (n=12) showed 
development of liver tumors by day 14. 88% (7/8), 70% (7/10), and 92% (11/12) of 
animals receiving intratumoral treatment of their primary tumors with MME alone, 
oncolytic virus alone, and combination treatment developed liver tumors, 
respectively. All treatments seemed to decrease the growth of liver metastases 
equally in comparison to untreated mock animals, resulting in smaller tumor size. 
However, in comparison to untreated animals, statistical significance was achieved 
only in groups treated with oncolytic virus alone and protease alone. No statistically 
significant differences in the numbers of liver tumors were seen among the groups. 
The present experiment did not show that the treatments would lead to an 
important  increase  of  metastases  compared to  the control,  probably because of  the 
big variability within every group.This points out that variability of the number and, 
especially, total volume of metastases could be a limitation for the animal model, 
since  it  could  demand  bigger  number  of  animals  for  drugs  that  do  not  present  a  
strong anti- or pro-metastatic effect. Animals did not show signs of post-treatment 
distress in any treatment groups. 
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5. SUMMARY AND CONCLUSIONS 
The work reported in this Doctoral Thesis seeks to improve adenovirus-based viral 
vectors for the treatment of cancer. While the first part focused on modifying vector 
biodistribution towards an improved cancer targeting / toxicity balance, in the 
second part  we propose the use of  proteolytic  adjuvants  in  order  to  increase  viral  
distribution after local injection into the tumor mass. In addition, we validated a 
new murine model of colorectal cancer that permits to detect possible increases in 
primary tumor metastasis potential as an adverse effect of proteolytic treatment. 
The RGD-motif located in the penton base is responsible for viral internalization 
and, when artificially displayed in the knob domain, can increase transduction of 
cancer cells, whose cellular membranes are rich in integrins. At the same time, 
KKTK-domain  in  the  shaft  has  a  major  role  in  liver  transfection  in vivo. 
Simultaneous ablation of liver targeting by KKTK-domain removal and tumor 
targeting by RGD display in different parts of the fiber was thus considered. The 
importance of the KKTK motif in vivo was corroborated since a 142-fold reduction 
on liver tropism with AdTLG, whose  KKTK-motif was substituted for GATK, was 
detected  in  comparison  with  a  wild  type  capsid  virus  (AdTL).  Unfortunately,  the  
striking decrease in liver targeting was accompanied by a substantial decrease in 
tumor transduction. In order to correct this drawback, we included a RGD motif in 
the fiber shaft by substitution of the KKTK-domain for RGDK. While the new virus 
could only decrease liver targeting 6-fold compared to wild-type virus, the 
infectivity of cancer cells in vitro was in general higher than with AdTLG and the in 
vivo transduction to subcutaneous tumors increased 3-fold. These improvements 
were associated with an improved capability of the virus to reduce tumor volumes 
and increase the survival of the mice in comparison with wild-type capsid vectors. 
Once the adenovirus vector reaches the target, an efficient spreading throughout 
the  tumor  mass  is  important.  A  panel  of  proteases  was  used  for  co-injection  with  
the oncolytic virus Ad5-?24-RGD: relaxin, hyaluronidase, elastase and macrophage 
metalloelastase (MME). Among them, MME increased tumor volume reduction 
after  viral  treatment  of  a  subcutaneous  model  of  colorectal  cancer  made  by  
implantation of HCT116 cells. Further tests in a metastatic colorectal cancer model 
not only proved the utility of MME in mono- or in combination therapy, but proved 
to be safe too for it did not induce a significant increase in the metastatic potential 
of the cancer.  
The work performed here with tumor stroma degrading proteases demands from  
accurate models to study tumor microenvironmental changes after experimental 
therapies.  In  this  regard,  a  novel  murine  model  of  human  colorectal  cancer  was  
constructed by intrasplenic injection of the carcinoma cell line HT29. Primary tumor 
growth showed small variability among subjects when using the correct mouse 
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strain and provider. Besides, an optimized MRI protocol permitted us to follow up 
the primary tumor growth and the development of liver metastases over a detection 
limit  as  small  as  0,7  mm  (tumor  diameter).  The  primary  tumor  growth  and  
subsequent progression to metastases was clear and well defined: for every mouse, 
between one to three weeks, passed between the detection of the primary tumor 
until the first liver metastases. This offers a broad window to administer the study 
treatment before metastases start and confirms the metastatic origin of the hepatic 
tumors.  The model  was indeed capable  of  evaluating the antitumor potential  and 
influence of an oncolytic adenovirus on the number and total volume of metastases. 
All in all, the development of novel oncolytic viruses by capsid modifications, 
which can be applied to non-replicating vectors for therapeutic gene transfer, offers 
the possibility to construct stable vectors with a more beneficial tropism for 
therapeutic purposes. This approach can be combined with the use of proteases. 
Particularly, the use of MME is suggested for improved intratumoral spreading of 
the  virus.  Further  investigations  should  assess  whether  a  stronger  degradation  of  
the tumor microenvironment by higher doses of MME would significantly improve 
tumor rejection by the oncolytic virus and also if, still, no influence on tumor 
progression and metastases  would be observed.  In  addition,  more research on the 
effects of MME per se on tumor cells and tumor tissue in general would be desirable. 
The new murine model presented here can assist the development of this type of 
work, and be useful for the study of new factors influencing tumor progression to 
metastases.  
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